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SUMMARY-
Carbamazepine is a drug which is now widely used for the 
treatment of both generalised epilepsy (tonic-clonic seizures) 
and partial epilepsy (with simple or complex symptomatology). 
This study was undertaken in an attempt to assess the role 
of the metabolites of carbamazepine, viz. 10, 11-epoxy-carbama-
zepine and 10, 11-dihydro-10,11-dihydroxy-carbamazepine, with 
regard to their therapeutic efficacy and the occurrence of 
side effects of the parent drug. It was also designed to seek 
a possible explanation as to why certain patients with optimal 
levels of carbamazepine in plasma fail to respond to therapy. 
A total of 23 epileptic patients (11 females and 12 males) 
suffering from either generalised (tonic~clonic) seizures or 
partial complex seizures took part in the study. The patients 
were divided into two groups according to their seizure frequency: 
Responders - those patients who had no seizures in the 
month prior to entry into the study (12 patients). 
Non-Responders - those patients who had a minimum of one 
seizure a week in the month prior to entry into the 
study (11 patients). 
Carbamazepine and its metabolites were monitored between 
·s a.m. and 6 p.m. by taking blood samples at two hourly 
intervals. Cerebrospinal fluid (CSF) was also obtained from 
seven patients in the non-responder group. The drug and its 
metabolites were assayed simultaneously by the thin-layer 
chromatographic (TLC) method of Hundt and Clark (1975). 
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Six of the 23 epileptic patients complained of side effects: 
nausea and headaches were the most frequently mentioned 
complaint. Statistical analysis showed, however, that there was 
no significant difference in the peak levels of carbamazepine 
and metabolites in patients both with or without side effects. 
Therefore it was not possible to define a threshold level of 
the drug above which side effects were likely to occur. Also no 
definite conclusion could be reached as to whether the metabolites 
play a role in the manifestation of side effects. 
The area under the curve (AUC) is a measure of the 
overall plasma concentration of carbamazepine and metabolites 
(present between 8 a.m. and 6 p.m.) in the individual patients 
of the two groups. There was no significant difference in the 
AUC of carbamazepine between responders and non-responders. 
However, the AUC of the dihydroxy and epoxy metabolites was 
significantly higher in the non-responders (P<-0.002 and P < 0.02 
respectively). Moreover in the CSF sampes of the non-responders, 
the mean (±SD) ratio of the dihydroxy metabolite to the parent 
drug was as high as 1.17 (±0,36). 
The results show a clear association between high levels of 
metabolites and poor response to carbamazepine therapy. 
Furthermore it would seem that either both metabolites are 
inactive or that if the epoxy metabolite is active as in the rat 
IX 
(Frigerio and Morselli 1975), any likely therapeutic effect is 
counter-acted by the relatively large concentration of inactive 
dihydroxy metabolite (Schmutz et al 1979). Moreover, it may 
follow that non-response to carbamazepine - despite optimal 
levels of the drug in plasma - may be due to competition by 
inactive dihydroxy metabolite for the site (s) of action of 
the parent drug in the brain. Research stratergies which might 
be used to test this hypothesis have been proposed. 
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CHAPTER ONE 
INTRODUCTION AND LITERATURE REVIEW 
CHAPTER ONE 
1.1. Introduction 
Carbamazepine was first synthesised in the laboratory 
of J.R. Geigy AG (Basel, Switzerland) in 1952. In the early 
1960 1 s it underwent extensive tests in animals (Theobald and 
Kunz 1963; Lorge 1963; Jongmans 1964) and was found to 
possess powerful anticonvulsant properties. The drug came 
into clinical use in 1963, for the treatment of epilepsy, in 
Great Britain and Europe. In 1968 it came into use in America 
for the relief of the pain of trigeminal neuralgia. It was 
only in 1974 that the marketing of carbamazepine for use in 
the treatment of epilepsy was approved by the Food and Drug 
Administration (FDA) of the U.S. Department of Health, 
Education and Welfare. 
In epilepsy, carbamazepine is now used quite extensively 
in the treatment of generalised (tonic-clonic) seizures and 
partial seizures (with elementary or complex symptomatology). 
In its two-dimensional structure, carbamazepine is quite 
dissimilar to the older anticonvulsants diphenylhydantoin and 
phenobarbitone (Fig. 1). However, in making a structural 
comparison between two compounds, one has to view the three-
dimensional structure as w~ll (Fig. 2). On doing so, one 
notes that the structural differences between carbamazepine 
and diphenylhydantoin may be more apparent than real (Julien 
and Hollister 1975). 
2 
N 
I 
CO-NH2 
Carbamazepine 
NH HL{ 
0 
0 
H 
NAo 
H 0 
Diphenylhydantoin Phenobarbitone 
Fig. 1 Chemical structures of carbamazepine, diphenylhydantoin, 
and phenobarbitone. 
Fig. 2 A. Xolecular models of diphenylhydantoin and carbamazepine. 
B. Superimposed models to illustrate three-dimensional 
similarity. (Adapted from Julien and Hollister 1975). 
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Since the two structures can be superimposed, it seems 
likely that the two drugs should have similar pharmacologic 
properties; in fact both are powerful anticonvulsants, both 
have the ability to alleviate intractable pain (e.g. in 
trigeminal neuralgia) and both depress digitalis-induced 
ventricular arrhythmias. However, carbamazepine differs from 
diphenylhydantoin in one important aspect: the phenyl rings 
of carbamazepine are rigidly fixed by the ethylidene bridge 
and this means that unlike diphenylhydantoin it has no 
behavioural depressant properties which diphenylhydantoin 
shares with the barbiturates. 
This important property of carbamazepine together with 
its ability to depress convulsive activity has made it a 
valuable drug in the change from polypharmacy to monotherapy 
in the treatment of epilepsy. 
Carbamazepine is a drug which is almost completely 
metabolised in the body. The two major metabolites that are 
present in plasma are: 10,11-epoxy-carbamazepine (EPOXY-CBZ) 
and 10,ll-dihydro-10,11-dihydroxy-carbamazepine (DI-OH-CBZ) 
(Fig. 3). 
Unlike the majority of epoxides, the epoxide metabolite 
of carbamazepine is comparatively stable and seems no more 
toxic than carbamazepine itself (Glatt et al 1975). EPOXY-CEZ 
has been shown to possess definite anticonvulsive properties 
in rats (frigerio and Morselli 1975), but it is still not 
certain whether this metabolite plays a role in the overall 
anticonvulsant effect of carbamazepine in man. 
4 
0 
1 CO-NH2 
10, 11-Epoxy-Carbamazepine 
N 
.OH 
/ 
/ 
I 
CO-NH2 
10,11-Dihydro-10,11-Dihydroxy-Carbamazepine 
Fig. 3 Chemical structures of 10,11-epoxy-carbamazepine and 10,ll-dihydro-
10,11-dihydroxy-carbamazepine. 
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DI-OH-CBZ is formed by the enzymatic cleavage of the 
epoxide metabolite. It has no anticonvulsant activity (Schmutz 
et al 1979). However, although it is a polar metabolite 
it persists in plasma in measurable quantities 15-24 hours 
after a dose and is even present in cerebrospinal fluid. 
This metabolite may therefore be in part responsible 
for the side-effects and toxicity sometimes encountered 
with carbamazepine therapy. 
1.2. Aims of the Study 
This project was designed to investigate: 
(a) To what extent the metabolites of carbamazepine play 
a role in the therapeutic efficacy and side-effects 
of the drug. 
(b) To discover a possible explanation as to why certain 
patients with optimal levels of the drug in plasma do 
not respond to therapy. 
There are very few reports in the literature in which 
the metabolites of carbamazepine have been monitored during 
therapy with the drug. In most of these studies no definite 
conclusion was reached as to the part played by the metabolites 
in the therapeutic efficacy and side-effects of carbamazepine. 
There are no reports on studies carried out on non-responders 
to carbamazepine. 
1.3. Review of the Literature 
1.3.1. Anticonvulsant Efficacy of carbamazepine 
The first controlled trial to evaluate the efficacy 
of carbamazepine as a new anticonvulsant was reported by 
Bird et al (1966). The study was carried out double blind 
for a period of 18 months in 45 mentally sub-normal in-
patients suffering from generalised (tonic-clonic) seizures. 
Twenty-four of these patients were started on carbarnazepine 
and gradually weaned away from the other anticonvulsants 
until they were on carbamazepine monotherapy. The remaining 
21 patients acted as the control group and consisted of 
patients taking phenobarbitone, diphenylhydantoin and primidone 
either alone or in combination. After the trial period there 
was a 26% improvement in the seizure frequency in patients taking 
carbamazepine alone and 16% improvement in the control group. 
The results are not statistically significant; however, they 
suggest that carbarnazepine has an equivalent anticonvulsant 
action to the older drugs. Side-effects were rarely 
reported; they included anorexia in one patient in the 
carbamazepine and control groups and loss of balance (1-3 days) 
in 2 patients in the carbamazepine group and one patient in 
the control group. No haematological abnormalities were 
detected in any of the patients taking part in the trial. 
In America, although carbarnazepine came into clinical 
use in 1974 for the treatment of epilepsy, a trial was 
reported by Livingstone et al (1967) to evaluate its 
potential use. Eighty-seven patients suffering from various 
forms of epileptic seizures took part in the trial. They 
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had all been refractory to treatment with one or more of 
the standard epileptic drugs, 20 of the patients became 
completely seizure-free, 37 failed to respond to therapy, 
30 showed marked improvement. Carbamazepine was found to be 
particularly useful in the control of psychomotor (temporal 
lobe) epilepsy. In addition to its anticonvulsant properties 
carbamazepine also produced a marked improvement in behaviour 
and personality in some patients. The trial also showed that 
carbamazepine could produce various forms of side-effects 
during its use. The most prominent of these was diplopia. 
8 
In most cases this reaction occurred in the early stages of 
treatment and disappeared spontaneously. Other untoward 
reactions encountered were transient blurred vision, drowsiness, 
ataxia and leucopenia. 
In South Africa, carbamazepine came into clinical use 
in the late sixties and a long-term clinical trial was 
reported by Wulfsohn (1972), to determine its value as an 
anticonvulsant and psychotropic drug. The patient population 
was 29 white adult males suffering from generalised (tonic-
clonic)seizures who had proved refractory to treatment with 
two or more anticonvulsant drugs. In 26 out of the 29 patients 
a marked improvement in the seizure frequency was reported 
over a period of 2~ years on addition of carbamazepine to the 
treatment regimen. In 2 patients seizures remained unchanged 
and one deteriorated. Psychotropic improvement (mood, 
sociability, work capacity and personality) was equally 
striking: 27 of the 29 patients improved, often dramatically, 
and none deteriorated. Side-effects encountered included mild 
initial nausea and dizziness in two cases. The author points 
out that this could either have been due to good toleration 
or to the fact that the group as a whole was mentally 
disturbed. 
After carbamazepine was initially introduced, its full 
acceptance as a new anticonvulsant was delayed because several 
reports about the occurrence of aplastic anaemia with its use 
appeared in the literature (Spillane 1964; Donaldson and 
Graham 1965; Dyer 1966; Saleh and Medes de Leon 1968; 
9 
Fellows 1969). It is noteworthy that since 1969 there have 
been no reported cases of aplastic anaemia and it remains 
questionable as to whether or not carbamazepine was responsible 
for those anaemias. 
1.3.1.1. Studies of Efficacy in Children 
The first trial in children was reported by Scheffner 
and Schiefer (1972). Seventy-four children aged between 1 
and 15 years were treated for period of 2 to 7 years with 
carbamazepine in combination with the standard anticonvulsant 
drugs. Two-thirds of the children had generalised (tonic-
clonic) seizures and the rest partial seizures (focal and 
psychomotor). Eighty-nine percent of the children became 
seizure-free one to three years after the start of 
carbamazepine therapy. 
The daily dose necessary to achieve freedom from seizures 
depended on body weight. Children weighing 10-20 kg required 
a mean of 24 mg/kg, or roughly twice the dose (11 mg/kg) 
necessary for children weighing 50-60 kg. 
No side-effects were encountered during therapy. The 
only significant changes in the electroencephalogram (EEG) 
during treatment with carbamazepine were a decrease in focal 
spikes in children 9-12 years old, and a diminished incidence 
of focal slowing in all children. 
In Israel a study was carried out to investigate the 
effectiveness of carbamazepine as the sole drug in the focal 
epilepsy of childhood, comparing it with diphenylhydantoin and 
the barbiturates (Lerman and Kivity-Ephraim 1974). 
In all 40 patients were studied in the age range 4-11 
years. Twelve patients had carbamazepine as their first and 
only drug whereas in the others various other drugs and drug 
combinations had previously been administered. 
After the trial period of 26 months, 32 patients were 
seizure-free from the initial dosage of carbamazepine. In 
six, seizures ceased when the dose was increased (the maximum. 
was 600 mg/day) and the remaining two had neglected to take 
their medication. In 80% of the children with behavioural 
problems, behaviour improved when carbamazepine was given. 
Only one child developed a rash on carbamazepine and no 
other side-effects were observed. EEG improvement occurred 
in 25% of the patients but in the remaining cases the focus 
persisted although the patients remained seizure-free. 
Numerous other reports dealing with the effectiveness of 
carbamazepine in the treatment of epilepsy in childhood have 
since been published (Grant 1972; Rett 1973; Gamstorp 1976). 
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1.3.2. Psychotropic effect of carbamazepine 
Carbamazepine is a drug which is closely related in its 
two-dimensional structure to the psychotherapeutic agent 
imipramine (Fig. 4). 
The early clinical trials (Livingstone et al 1966; 
Pryse-Philips and Jeavons 1970; Wulfsohn 1972) reported that 
patients using carbamazepine experienced a beneficial effect 
on behaviour (diminuition of aggressiveness, improved co-
operation in the wards, etc.) and in performance (increase 
in alertness, measured abilities, etc.). These observations 
were attributed to the tricyclic structure of carbamazepine. 
However, there could have been two possible explanations 
for this positive psychotropic effect of carbamazepine: 
firstly, in all these studies carbamazepine had been 
substituted for the more intoxicating anticonvulsants, for 
example, phenobarbitone and diphenylhydantoin. Secondly, 
the improvement in seizure frequency by the addition of 
carbamazepine to the treatment regimen could well have 
accounted for the improvement in behaviour and performance. 
Rett et al (1976) reported on a long-term pharmaco-
psychological investigation carried out to establish whether 
carbamazepine did indeed have a psychotropic effect. The 
patient population consisted of 30 children and adolescents 
(12 girls and 18 boys) suffering from generalised (tonic-
clonic) seizures. They were divided into three groups: 
11 
12 
\ 
CO NH2 Cabamazepine 
Clii CH 
N 
I 
CH2 I 
CH2 I 
CH2 I 
N "'-. d( CH, lmipramine 
Fig. 4: Chemical structures of carbamazepine and imipramine. 
Group A: Patients who had previously been treated with pheno-
barbitone, phenytoin and primidone in various 
combinations before receiving CBZ monotherapy. 
Group B: Patients who had not received any anticonvulsants 
for at least 6 months before entry into the study. 
Group C: Patients taking primidone, mephenytoin and phenytoin 
either alone or in combination. 
The group A patients had their first psychological 
examination while they were still receiving their previous 
treatment. They were then transferred over a period of 1 to 
13 
2 weeks to carbamazepine monotherapy. The second psychological 
investigation was undertaken 11-12 months later. 
The psychological examination involved the following 
tests: 
(a) Hamburg-Wechsler Intelligence scale for children: 
Verbal IQ, Practical IQ and Overall IQ. 
(b) Walther test: Psychomotor function. 
(c) Rorschach test: Activity and psychic manifestations. 
At the end of the 12 month trial period no change could 
be demonstrated in the group A patients. No significant 
change was demonstrable in the group C patients although 
there was a trend towards improvement in a number of tests. 
The group B patients showed a significant improvement in the 
Walther test and this was the only evidence that could be 
found for a possible psychotropic effect for carbamazepine. 
No other studies have been reported since on the possible 
beneficial psychotropic effect of carbamazepine in epileptic 
patients. Therefore this question is still a controversial 
subject. 
1.3.3. EEG Studies 
Patients on phenobarbitone and diphenylhydantoin often 
show a marked improvement in their electroencephalographic 
(EEG) tracings when they respond to therapy (Buchthal and 
Svensmark 1960-1). 
A double-blind study was therefore undertaken to compare 
the effect of carbamazepine and placebo on the EEG and fit 
frequency of a group of long-stay epileptic patients in a 
psychiatric hospital (Pryse-Phillips and Jeavons 1970). 
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All patients had epilepsy of partial (temporal lobe) or 
generalised type and were allocated randomly to receive either 
carbamazepine or an identical placebo. The first EEG record, 
which included the response to hyperventilation and photic 
stimulation, was made before the administration of carbamazepine 
or placebo, the second after the patients had received 600 mg 
daily for a month and the third a month after the drug had 
been discontinued. 
At the end of the trial period, no EEG improvement was 
seen among the patients taking carbamazepine. In fact in 20% 
of the patients the EEG was worse (i.e. a greater increase in 
focal spiking) while they were receiving the drug, and the 
EEG abnormality disappeared after the drug was discontinued. 
No correlation could be found between the EEG findings and 
the frequency of seizures. 
Ferrer-Vidal et al (1976) investigated whether there 
was a correlation between EEG background activity and serum 
levels of carbamazepine and phenobarbitone. Fifty patients 
took part in the study and EEG background activity was 
evaluated on the same days as the serum level determination 
of carbamazepine and phenobarbitone. 
It was found that there was no correlation between the 
slowing down of background activity and the serum levels of 
carbamazepine. On the other hand, high serum levels of pheno-
barbitone did go hand in hand with lower EEG background 
activity, while serum phenoba+b levels of less than 30 µg/ml 
were associated with normal EEG background activity of 8,5 Hz. 
In a long-term study carried out over a period of 12 
months, Monaco et al (1979) analysed the EEG tracings in 20 
epileptic patients suffering from either generalised or 
partial seizures. The patients received carbamazepine either 
alone or in combination with phenobarbitone and/or phenytoin 
and/or clonazepam. EEG was performed twice monthly. 
The findings suggested that the majority of the tracings 
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do not worsen, but nor do they improve. The majority of the 
patients displaying freedom from seizures had good carbamazepine 
plasma levels and an irregular EEG tracing. 
The authors therefore concluded that EEG was of little 
value in assessing the clinical picture of patients on 
carbamazepine. 
1 . 3 . 4 . Serum levels 
In the present day management of epilepsy, serum level 
determination of anticonvulsants play an important role; the 
physician can ensure that the patient is compliant or that he 
is receiving a high enough dose to be therapeutic but not 
toxic. 
Our current knowledge of the therapeutic serum concen-
trations of carbamazepine comes from a variety of studies and 
clinical trials. 
Frey and Yryana (1970) were the first people to report 
a therapeutic concentration for carbamazepine. They measured 
carbamazepine in serum by the method of Hermann and Geigy 
(1965), in 23 adult epileptic patients receiving 400-1 000 mg/ 
day of the drug. Serum titres of 1-13 µg/ml (average 5 µg/ml) 
were obtained. About 60% of the serum concentrations were 
from 4-6 µg/ml, 20% from 7-10 µg/ml and 8% from 1-3 µg/ml. 
The highest single value was 13 µg/ml. All the above levels 
were associated with seizure control. The authors point out 
that no cases of carbamazepine intoxication were included in 
their study. 
Parsonage (1972) determined carbamazepine concentrations 
by the method of Gardner-Thorpe et al (1972) in 48 children 
and adults. He concluded that there was no relationship 
between serum concentrations and degree of seizure control. 
Dosage range was 100 to 1 400 mg/day and serum concentrations 
ranged from non-detectable to 11,8 µg/ml. Only one patient 
was receiving carbamazepine as sole drug (400 mg/day) and the 
level was 8,8 µg/ml, but the seizures were not controlled 
(as cited by Cereghino 1975). 
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Meinardi (1972) studied the correlation between serum 
carbamazepine levels and clinical control and side-effects in 
six epileptic patients. He predicted that 50% of all patients 
on carbamazepine will suffer side-effects such as diplopia, 
ataxia, headaches and dizziness at serum levels of 8,5-10 µg/ 
ml whereas nystagmus could occur at much lower serum levels 
(1,5 µg/ml) in an appreciable number of patients. 
Johannessen and Strandjord (1973) reported carbamazepine 
concentrations in serum and CSF of 19 adult epileptic patients 
(8 women and 11 men), and their relation with dosage in 
mg/kg body weight. Serum and CSF samples were taken before 
the morning dose and carbamazepine was determined by a 
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modified Hermann and Geigy method (1965). The mean concentrations 
of carbamazepine in serum and CSF were 7,6 and 1,7 µg/ml, 
respectively, without any significant differences between men 
and women. Because of the low protein content of CSF, the 
concentration in CSF can be taken as the therapeutically 
active unbound fraction of the drug. This was found to be 
22 ± 5% of the total serum concentration. The ratio between 
dosage in mg/kg and concentration of carbamazepine in serum 
showed marked individual differences and, therefore, the 
authors advised that dosage should be adjusted according to 
the serum level in each patient. 
Two independent studies carried out in America, to 
evaluate the efficacy of carbamazepine for epilepsy, included 
serum level determination as part of their clinical trial 
protocols. Cereghino et al (1974) studied 36 institutionalised 
adults receiving 1 200 mg of carbarnazepine daily for a period 
of 21 days. Serum concentrations ranged up to 13,7 µg/ml, 
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with half the values ranging from 5,8-9 µg/ml. Troupin et al 
(1974) studied carbarnazepine in 12 patients, aged 19-54 years. 
Mean oral dosage was 16,8±4 mg/kg, and mean serum concentration 
was 10,7 µg/ml. In both studies, a wide variety of side-
effects was encountered, especially on initiation of therapy, 
but not severe enough to discontinue the drug. No mention is 
made as to the serum levels at which these side-effects 
occurred. 
Schneider (1975) investigated whether there was a 
correlation between early morning ('fasting') serum levels 
of carbarnazepine and the degree of seizure control, and also 
at what serum levels side-effects occurred. (Samples were 
taken 3 hours after the morning dose for this latter 
correlation.) Of the patients studied, 94 were hospitalised 
and 75 institutionalised, i.e. had been under observation 
for many years. Carbarnazepine was estimated by the method of 
Hermann (1965). Good seizure control was obtained with mean 
serum levels of 4,6±1,3 µg/ml in institutionalised and 6,5±3,0 
µg/ml in hospitalised patients. Carbarnazepine serum levels 
related to the first appearance of side-effects such as 
drowsiness, ataxia and diplopia, averaged 11,6±4 µg/ml. The 
threshold level above which side-effects were likely to occur 
was estimated to be 8,9 µg/ml in serum. 
Eichelbaum et al (1976) reported plasma levels of carba-
mazepine and one of its main metabolites, carbarnazepine-10,11-
epoxide, during treatment of epilepsy. Twenty-five patients 
suffering from complex partial seizures with or without 
generalization of the seizures took part in the study. The 
mean dose of carbarnazepine was 12,5±3,3 mg/kg body weight. 
Blood samples were collected before the morning dose and 
carbamazepine and its epoxide metabolite were assayed by a 
liquid chromatography method of Eichelbaum and Bertilsson 
(1974). The mean concentration of carbamazepine and its 
epoxide metabolite were 5,4±2,5 µg/ml and 1,1±0,42 µg/ml, 
respectively. In two patients simultaneous measurements in 
CSF and plasma were carried out. The ratio between the con-
centration of carbamazepine in CSF to plasma was of the order 
of 0,22 as compared to 0,45 for the epoxide. The authors 
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point out that the larger unbound fraction of the epoxide 
suggests that this metabolite could contribute to the anti-
convulsant effect of carbamazepine if it is as active in man as 
in rats (Frigerio and Morselli 1975). 
Monaco et al (1976) monitored carbamazepine levels weekly 
over a period of nine weeks in 20 epileptic patients un-
responsive to treatment. The patients received carbamazepine 
either alone or in combination with phenobarbitone and/or 
phenytoin. Carbamazepine was administered either twice or 
three times daily according to the individual needs, in doses 
of 5-24 mg/kg body weight. Blood samples were collected twice 
daily at 8 a.m. and 6 p.m. and the concentration of carba-
mazepine and its epoxide determined by a gas chromatography 
method of Morselli et al (1975). No attempt was made to alter 
phenytoin or phenobarbitone levels; emphasis was on achieving 
carbamazepine levels of 4-10 µg/ml. Within 2-3 weeks of 
monitoring, there was a remarkable drop in the seizure 
frequency with carbamazepine plasma levels in the desired 
range. There was no relationship between the epoxide and 
carbamazepine concentrations. This study showed a definite 
improvement in the seizure frequency could be achieved if 
carbarnazepine levels were kept in the therapeutic range 
defined by the authors. 
Darn et al (1977) reported on a study carried out to 
evaluate whether carbarnazepine-10,11-epoxide had an indepen-
dent anti-epileptic activity in man. The patient population 
included 132 epileptic out-patients treated for 1 to 8 years 
with carbarnazepine alone or in combination with phenytoin, 
phenobarbitone or both. One hundred and eighteen patients 
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had generalised (tonic-clonic) seizures and 57 had partial 
seizures with complex symptomatology. Carbarnazepine and its 
epoxide were determined by a TLC method described by 
Christianssen (1973). A significantly higher level of epoxide 
was found in patients on combined treatment compared with 
patients on carbarnazepine alone. However, no significant 
difference in epoxide levels could be demonstrated between the 
patients whose seizures were well controlled and those who were 
non-responders to carbarnazepine. Hence, it appeared that the 
epoxide had no additional anti-convulsant properties in man. 
In most studies dealing with serum levels and seizure 
control, so far described, carbarnazepine was used in combination 
with other anticonvulsant drugs. Callaghan et al (1978) 
carried out a study in which carbarnazepine was used as a single 
drug in the treatment of epilepsy. Thirty-two patients with 
a variety of seizures took part in the study. Blood samples 
were collected at intervals which varied from 1 to 8 hours 
. 
after the last dose of carbarnazepine, and serum levels 
were measured by gas liquid chromatography according to 
the method of Rogers et al (1973). 
became completely seizure-free and 
Thirteen patients 
10 had a greater than 50% reduction in seizures. The range 
of levels associated with: (i) no seizures was 1,2-8,1 µg/ml; 
(ii) greater than 50% reduction in seizures 5,7-12,6 µ.g/ml; and 
(iii) in non-responders 7,4-20,5 µg/ml.The study therefore 
failed to define a therapeutic range for carbamazepine as a 
wide range of serum levels was associated with freedom from 
seizures. This discrepancy could have arisen as a result of 
the wide variation in sampling times. 
Monaco et al (1979) reported on a long-term study on 
carbarnazepine in which the relationship between drug plasma 
levels, EEG and adverse reactions were studied over a 12 
month monitoring period. Carbamazepine was used as mono-
therapy or in combination with phenobarbitone and/or phenytoin 
and/or clonazepam. The subjects taking part in the study 
included 16 adults and 4 children, suffering from generalised 
or partial seizures. Blood samples were collected at 8 a.m. 
and 6 p.m. on one day per month, and plasma levels of carba-
mazepine and the epoxide were determined according to the 
method of Morselli et al (1973). The mean seizure frequency 
decreased from 6,6 seizures per year to 1,2 seizures per year 
on inclusion of carbarnazepine in the study. The therapeutic 
level of carbamazepine was found to be 7-9 µg/ml. The 
epoxide metabolite was found to be present in those patients 
whose carbamazepine plasma levels exceeded 4-5 µg/ml. 
However, no correlation could be found between the type of 
EEG pattern and the plasma levels of carbamazepine. In this 
study it was shown that the efficacy of carbarnazepine was 
prolonged and constant particularly in patients on monotherapy 
and the authors point out that the treatment of epilepsy should 
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as far as possible begin with one drug alone - carbamazepine. 
Hoppener et al (1980) carried out a study to determine 
whether there was a correlation between the daily fluctuations 
in carbamazepine serum levels and intermittent side-effects. 
Sixty-two patients using carbamazepine either alone or in 
combination with other anticonvulsants and experiencing side-
effects such as drowsiness, diplopia and headaches, took part 
in the study. Carbamazepine was administered three times a 
day and blood samples were collected at 2 hour intervals 
starting just before the morning dose at 8 a.m. and ending at 
6 p.m. Serum levels were determined by gas chromatography 
using the method described by Cramers et al (1976). Each 
patient showed a more or less prominent increase in serum 
levels 2 hours after intake. In the afternoon a maximum was 
reached, often attended by side-effects. After changing the 
mode of administration (reducing the lunchtime dose) and the 
serum level remaining below 8 µg/ml, the side-effects dis-
appeared. None of the patients showed an increase in seizure 
frequency after this change. 
Johannessen and Strandjord (1980) reported a therapeutic 
serum concentration of 3,1-12,1 p.g/ml for carbamazepine. This 
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was derived from a study in which carbamazepine was used as a 
sole drug in the treatment of epilepsy in 62 patients. Serum 
concentrations of carbamazepine and its epoxy metabolite were 
determined by enzyme immunoassay and gas chromatography, 
respectively, in fasting morning blood specimens. Of the 62 
patients, 49 became seizure-free while 13 remained non-responders 
to the drug even with optimal serum levels of carbamazepine and 
the epoxide. No reasons were given for this discrepancy. 
1.3.5. Toxicity of carbamazepine 
Anticonvulsant drugs are administered in physiologically 
active doses to epileptic patients over prolonged periods of 
time and patients may even take daily doses throughout most 
of their lifetime. Such prolonged therapy with a rather 
potent pharmacological agent is likely to affect not only 
the central nervous system but normal physiologic functions 
as well. The toxicologic effect produced in patients taking 
an anticonvulsant drug, which in this case is carbamazepine, 
can be divided into different groups: 
(1) Acute - resulting from drug overdosage. 
(2) Idiosyncratic drug reactions. 
(3) Drug interactions. 
(4) Teratogenic. 
1.3.5.1. Acute toxicity 
The therapeutic range for carbamazepine that has been 
put forward by the various clinical trials can be averaged 
out to be something like 4-12 µg/ml. This is of course 
subject to interindividual variations. Usually acute toxicity 
results when the upper limit of the therapeutic range is 
exceeded as a result of taking an overdosage of the drug 
whether iatrogenic, accidental or purposeful. In most cases, 
carbamazepine intoxication presents itself by clinical signs 
and symptoms of central nervous system dysfunction. The 
cerebello-vestibular and the pyramidal extrapyramidal systems 
are the ones that are greatly affected. Higher cortical 
function and reticulocortical activating system are only 
mildly disrupted (Wilder 1976). 
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Cerebello-vestibular dysfunction results in nystagmus, 
ataxia and incoordination. Extrapyramidal effects are un-
masked when toxicity becomes severe, the results of which are 
dystonic posturing, choreiform and athetoid movements and 
signs of asterixis. 
Since the introduction of carbamazepine in 1962, for the 
treatment of epilepsy and trigeminal neuralgia, there have 
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been relatively few cases reported of acute toxicity due to the 
drug. 
De Zeeuw (1979) reported on a severe case of carbamazepine 
intoxication in which 16 g of carbamazepine was ingested in 
an apparent suicide attempt. Plasma levels of the drug and 
its epoxy metabolite were monitored by HPLC. On admission, 
the patient was in a semicomatose state but arousable. After 
two days of treatment (gastric lavage and aspiration), the 
patient lapsed into deep coma and the plasma levels of 
carbamazepine and the epoxide were found to have increased 
from 29-44 µg/ml and 14-22 µg/ml, respectively. Rapid 
elimination of the drug then followed with complete recovery 
within 4 days. The authors point out that the anticholinergic 
and central depressant properties of carbamazepine could have 
brought about a marked decrease in intestinal motility 
resulting in a protracted absorption. When motility was 
restored, rapid absorption took place resulting in increased 
levels of the drug and its metabolite. They suggest that in 
cases of carbamazepine intoxication gastric lavage and 
aspiration should be carried out up to a period of 3-4 days 
after ingestion. 
Only two other reports have appeared in the literature 
giving details of the fate of the drug during carbamazepine 
intoxication (Gruska et al (1969) and Gulzow et al (1975)). 
However, the assay procedure used in these papers was based 
on the formation of 9-methylacridine and this therefore gave 
the sum of carbamazepine and carbamazepine epoxide in the blood. 
Jacome (1~79) reported on carbamazepine-induced dystonia 
in four patients suffering from intractable seizures. Three 
of the patients developed transient dystonia of the axial 
muscles, and one of the hands, after carbamazepine was added 
as anticonvulsant therapy. All the patients were taking more 
than 1 000 mg/day when the symptoms appeared. Serum levels 
of carbamazepine were not determined. 
Crosley et al (1979),in their paper on dystonia associated 
with carbamazepine administration in three brain-damaged 
children, point out that carbamazepine is a structural 
analogue of the phenothiazines and tricyclic antidepressant 
drugs. This could therefore mean that the production of 
dystonia and choreoathetoid movements is the result of carba-
mazepine having a direct antagonistic role at the dopamine 
receptors. 
A report was published in 1976, by Chadwick et al, on 
asterixis and cerebellar syndrome due to carbarnazepine 
intoxication. The case involved a patient taking 1 200 mg/day 
of carbarnazepine to control the pain of trigeminal neuralgia. 
On admission she had nystagrnus, moderate gait ataxia and 
asterixis of her outstretched hands. The serum level at the 
time was 41 µmol/1 (9,7 µg/ml). The dose of carbarnazepine 
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was gradually reduced to 800 mg/day. The asterixis improved 
but was still present. Serum carbamazepine level had fallen 
to 6 µmol/1 (1,7 µg/ml). On withdrawal of carbamazepine 
asterixis disappeared. 
In 1975, Troupin and Ojemann reported on a new syndrome -
paradoxical intoxication. They defined this as an increase 
in the seizure frequency as the blood level of the anti-
convulsant rises. This phenomenon is rare and can occur when 
using high doses of an anticonvulsant with resulting high serum 
levels to obtain seizure control. One case is described where 
carbamazepine was used as sole drug and an increase in seizure 
frequency (from O per month to 6 per month) occurred when the 
blood level of the patient exceeded 20 µg/ml. Reduction in 
dose and blood level resulted in a decrease in seizures. 
The authors make the point in their paper that this should 
not discourage the gradual increase in the dose in order to 
achieve a successful balance between seizure control and the 
usual medication side-effects. 
As far as toxicity is concerned, carb.amazepine is a 
relatively innocuous drug compared to the barbiturates and 
phenytoin. No deaths have so far been reported with 
carbamazepine overdosage. 
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1.3.5.2. Idiosyncratic drug reactions 
Idiosyncratic or adverse reactions to a drug refer to 
those reactions that are generally unpredictable when therapy 
is started. They are not related to dose and may occur at 
various stages in the course of treatment. Idiosyncratic 
reactions are rare but nevertheless important as many are 
serious, even potentially fatal. 
The adverse reactions to carbarnazepine will be classified 
according to the bodily systems affected: 
Organ or 
Organ System 
Skin 
Haematopoietic 
Autoimmune 
Liver and 
Kidney 
GIT Tract 
Cardiovascular 
Central Nervous 
System 
Adverse Reaction 
Exfoliative 
dermatitis 
Urticaria 
Leukopenia. 
Aplastic anaemia 
Thrornbocytopenia 
Lupus 
erythematosus 
reaction 
Thyroiditis 
Hepatitis 
Jaundice 
Water 
intoxication 
Nausea and 
vomiting 
Bradycardia 
Psychoses, e.g. 
hallucinations 
Mechanism 
Allergic 
Allergic or 
direct 
toxicity 
Allergic or 
direct 
toxicity 
References 
Houwezijl et 
al· (1978) 
Ramsay (1967) 
Gerber et al 
(1979) 
Rutman ( 19 7 8) 
Dyer et al 
(1966) 
Pisciotta 
( 19 7 5) 
Pearce ( 196 8) 
Takigawa 
(1976) 
Rootwelt 
(1978) 
Krudsen and 
Jensen (1979) 
Tur-Kaspa and 
Levo (1978) 
Peru cc a ( 19 7 8) 
Herzberg (1978) 
Berger (1971) 
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1.3.5.3. Drug interactions 
It is only in recent years that the dangers of drug 
interactions have been realised and despite the present 
enthusiasm for monotherapy in the treatmen_t of epilepsy, 
polypharmacy is still widely used. When anticonvulsant 
drugs or drugs for other disease states are added, the 
patient's reaction may not simply be caused by the added 
effects of the additional drug but by the interaction of the 
drug combination within the individual. 
The drug interactions that have so far been reported for 
carbamazepine ( CBZ) are listed below,: 
Interfering drug 
Phenytoin 
Phenobarbitone 
Primidone 
Warfarin 
Propoxyphene 
Triacetyl-
oleandomycin 
Lignocaine 
Quinidine 
Doxycycline 
Steroid contra-
ceptives 
Clinical significance 
Reduced therapeutic 
efficacy of CBZ, usually 
of little clinical 
significance because of 
the added effect of the 
interfering drug. 
Decreased serum warfarin 
and impaired hypothrombo-
nernic response. Reduction 
in warfarin half-life. 
Rise in serum levels of 
CBZ which may lead to 
toxicity. 
Therapeutic efficacy 
reduced by CBZ. 
Half-life reduced by CBZ 
therefore possibility of 
reduced anti-bacterial 
effect. 
• 
Reduced contraceptive 
efficacy 
References 
Christiansen and 
Dam (1973t 
Cereghino et al 
(1975) 
Johannessen et al 
(1975) 
Schneider (1975) 
Dam et al (1975) 
Rane et al (1975) 
Hansen et al 
(1971) 
Dam and 
Christiansen (1977) 
Dravet et al (1977) 
Perucca and 
Richens (1979) 
Penttilla et al 
( 19 7 4) 
Stockley (1976) 
Hempel and 
Klinger (1976) 
Interfering drug 
Monoarnine-
oxidase 
inhibitors (MAOI) 
Lithium 
Cimetidine 
Clinical significance 
No clinical reports of 
interactions have been 
reported but on theoreti-
cal grounds it may be 
dangerous to administer 
CBZ with MAOI 
Inhibition of lithium-
induced polyuria 
Inhibition of CBZ 
metabolism - may lead 
to toxicity 
1.3.5.4. Teratogenicity 
References 
Macallum (1980) 
Perucca and 
Richens (1980) 
Ghose (1980) 
Tellerman-Toppet 
et al (1981) 
Pregnancy complicates the problem of seizure control since 
a seizure during gestation could have disastrous effects on 
the developing foetus because of the consequent anoxia. The 
use of anti-epileptic drugs prophylactically is therefore 
extremely important. However, it has been shown that drugs 
like phenytoin, phenobarbitone, primidone and trimethadione 
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are unequivocally implicated in human dysmorphogenesis (Meadow 
1970; Meyers 1973; Annegers et al 1974; Yoshimbi et al 1980). 
In the case of carbarnazepine, Starreveld-Zimrnerman et al (1973) 
reported that there was a reduced incidence of malformations 
in mothers who took this drug alone, or in combination with 
other anticonvulsants during pregnancy. Hicks (1979), on 
the other hand, described one instance of defective organo-
genesis in the stillborn offspring of a mother who took 
carbarnazepine only in the first 6-8 weeks of pregnancy. 
It can therefore be seen that the literature neither con-
firms nor denies the teratogenicity of carbarnazepine and more 
studies are required to indicate a clear preference between no 
treatment and carbarnazepine, with carefully monitored serum 
levels, for epilepsy in pregnancy. 
1.3.6. Pharmacokinetics of carbamazepine 
Nowadays it is considered essential for rational therapy 
that the full pharmacokinetic profile of a drug should be 
known. This is because it has become evident that the extent 
to which a drug exerts its therapeutic, and even its toxic 
effects, depends on its biological availability and disposition 
in the body. 
The processes involved in getting a drug to its site of 
action and terminating its particular pharmacological effect 
can be summarized in the following schematic diagram: 
ADMINISTRATION 
SITE 
DISTRIBUTION 
ABSORPTION ~TOFAGE SITES 
I PLASMA l ACTION SITES 
~BIOTRANS-
FORMATION 
SITES 
EXCRETION SITES 
(Adapted from Tyrer 1980) 
1.3.6.1. Absorption and Bioavailability 
ELIMINATION 
Carbarnazepine is a drug which, from its physical and 
chemical properties, is classified as a neutral lipophilic 
compound. The absolute bioavailability of carbarnazepine in 
man has not been determined, because a preparation suitable 
for intravenous injection is not available. However, a study 
carried out by Faigle and Feldmann (1975), in which 400 mg of 
14 C-labelled carbarnazepine was administered to two healthy 
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volunteers, found that the oral bioavailability of the drug 
is more than 70%. This was based on the recovery of radio-
labelled carbamazepine in urine and faeces. 
Levy et al (1975) found that the bioavailability of 
carbamazepine could be increased by administering the tablets 
with meals because dissolution rather than disintegration is 
the crucial step for absorption. Solubility of the drug is 
increased by the bile secreted following a meal. 
The time to reach peak plasma concentration, Tmax' has 
been shown to vary from something like 6 to 24 hours, after 
single doses (Hvidberg and Dam 1976; Faigle et al 1976). 
However, it must be pointed out that the Tmax is the time at 
which the elimination of a drug comes to exceed its amount of 
absorption. It is therefore a measure of both the absorption 
rate and elimination rate of the drug. A drug does not 
necessarily have to reach its Tmax value in order to exert 
its particular pharmacological effect. A better parameter 
which can give an idea of how fast a drug is absorbed is the 
absorption half-life, T\abs' and for carbamazepine this is 
1,72 hours (Levy et al 1975). 
1.3.6.2. Plasma Protein Binding 
The plasma protein binding of carbamazepine has been 
measured by direct measurements (equilibrium dialysis and 
ultrafiltration) and by simultaneous drug concentrations in 
CSF and saliva, relative to drug concentration in whole plasma. 
There is rather good agreement between the various studies 
which gave protein binding of carbamazepine as 70 to 80% 
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(Johannessen and Strandjord 1972; Meinardi 1972; Di Salle 
et al 1974; Johannessen et al 1976). 
Hooper et al (1975) found that patients with hepatic 
disease had a significantly lower protein binding than patients 
without hepatic disease, but the difference was not large 
enough to be of practical importance. Renal disease had no 
influence on the extent of binding of carbamazepine to plasma 
proteins. 
Morselli et al (1975) and Rawlins et al (1975) showed 
that drugs like phenytoin and phenobarbitone, which are very 
often administered concomitantly with carbamazepine, had no 
influence on the protein binding of the latter. 
Schneider and Berenguer (1975) made simultaneous 
measurements of CSF and plasma concentrations of the two major 
metabolites of carbamazepine, viz. 10,11-epoxy-carbamazepine 
and 10,ll-dihydro-10,11-dihydroxy-carbamazepine. A mean (±SD) 
CSF/plasma ratio of 48,9±9,6% was found for the epoxy 
metabolite and 47±9,3% for the dihydroxy metabolite. Moreover, 
it was found that complex concurrent administration of other 
medications had no displacing effect on the extent of protein 
binding of the epoxy metabolite but in the case of the dihydroxy 
metabolite not only did the total amount increase but also 
its free fraction. 
1.3.6.3. Distribution 
Because carbamazepine is neutral, it is a fairly lipo-
philic compound and passes easily through membranes in the 
body. After single oral doses of carbamazepine to volunteers 
or patients, the approximate volume of distribution has been 
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found to vary between 0,79 to 1,86 l/kg body weight. These 
figures were calculated assuming complete bioavailability of 
the drug (Bertilsson 1978). 
1.3.6.4. Biotransformation 
Biotransformation is important for both the intensity and 
the duration of pharmacological effects since the rate limiting 
step of drug removal from the body is metabolism not excretion. 
As with other drugs, carbamazepine is reacted in the liver to 
form more polar metabolites which, being water soluble and 
able to be conjugated, are more readily excreted in bile and 
urine. 
The main pathways of metabolism of carbamazepine that 
have been identified are shown in fig. 5. 
Taking the total urinary radioactivity as 100%, the 
following approximate percentages are attributable to the 
different pathways: 
1. Epoxidation of the 10,11 double-bond 
of the azepine ring 
2. Hydroxylation of the six-membered 
aromatic rings 
3. Direct N-glucuronidation at the carbamoyl 
side-chain 
4. Substitution of the six-membered rings 
with sulphur-containing groups 
40% 
25% 
15% 
5% 
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Fig. 5. Major pathways for the biotransformation of carbamazepine in man. 
1.3.6.5. Elimination 
Only some 2% of the dose of carbamazepine is excreted 
unchanged in the urine (Faigle et al 1976); this means 
therefore that carbamazepine is eliminated from the body 
chiefly by biotransformation. 
The half-life, Ti., is the parameter that gives the best 
~ 
indication of the elimination rate. In the case of carbamaze-
pine, half-lives ranging from 24 to 46 hours were found in 
volunteers (Palmer et al 1978; Rawlins et al 1975). However, 
Eichelbaum et al (1975), in their study on four epileptic 
patients, showed that the half-life of carbamazepine decreased 
from 35 to 20 hours after a few weeks' treatment. This was 
confirmed by Morselli et al (1975) who showed that the post-
steady state plasma half-lives were approximately 15 hours 
in epileptic patients. The results from these studies suggest 
that carbamazepine induces its own metabolism (autoinduction). 
Unlike phenytoin, carbamazepine is eliminated by dose-
independent kinetics (Levy et al 1975; Rawlins et al 1975) 
and therefore saturation of the enzymes responsible for 
elimination is unlikely to occur with the dosages used 
therapeutically. 
Clearance is a measure of the amount of the drug 
eliminated per unit time. In two studies (Eichelbaum et al 
1975; Rawlins et al 1975), the mean plasma clearances were 
30 and 25 ml/min respectively. This suggests that a 'first 
pass' metabolism is negligible. 
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1.3.7. Putative Mode of action of carbamazepine 
1.3.7.1. Effects on seizure tests 
Carbamazepine displayed the ability to depress maximal 
electro-shock seizures (50-100 volts, 50 c.p.s. A.C., for 
0,63 secs applied through corneal electrodes) in both rats 
and mice (Koella et al 1976). In rats the oral ED 50 for 
suppression of tonic convulsions of the hind limbs was 10 mg/kg 
and in mice the En50 for this test was 12 mg/kg. In this study 
carbamazepine was administered 1 hour prior to electroshock 
and it was found to be maximally effective for at least four 
hours. 
In 'epilepsy models' involving chemically-induced 
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seizures, the potency of carbamazepine was less pronounced 
(Koella et al 1976). In mice challenged with picrotoxin in 
intraperitoneal doses of 12 mg/kg, carbamazepine in oral doses 
as high as 300 mg/kg was found to be ineffective. Carbamazepine 
inhibited convulsions produced by penetetazole (80 mg/kg 
i.p.); the ED50 was about 40 mg/kg. However, the percentage 
of mice protected did not increase with larger doses of 
carbamazepine. Against strychnine-induced convulsions, oral 
doses of 300 mg/kg of carbamazepine were not sufficient to 
inhibit convulsions completely. 
J·ulien and Hollister ( 1975) investigated the effect of penicillin-
induced epileptiform discharge and estrogen-induced spike-wave 
discharge (all in cats) and, in Rhesus monkeys, alurninium-
oxide-induced behavioural and electrographic seizures. 
It was found that while carbamazepine in doses of 2,5 
mg/kg significantly reduced penicillin-induced discharges, 
doses of 5 mg/kg virtually abolished such discharges. Blood 
levels of carbamazepine were in the range of 4-6,5 µg/ml. In 
no animal was a blood level greater than 9 µg/ml required to 
suppress epileptiform discharge. 
In the case of estrogen-induced epileptiform discharge, 
carbamazepine even in doses up to 30 mg/kg (blood levels 
greater than 15 µg/ml) was only partially effective in 
reducing the spike-wave discharge. 
In three Rhesus monkeys with aluminium-oxide-induced 
behavioural and electrographic seizures, carbamazepine (20 
mg/kg, i.m. daily, blood levels of 4-8 µg/ml) suppressed all 
convulsant activity in each of the three animals and returned 
the EEG patterns to normal. Such effect was reversible, 
and seizures returned within 10-16 days after cessation of 
drug administration. 
1.3.7.2. Cerebrospinal effects 
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Following electrical stimulation of various structures 
belonging to the limbic system (e.g. the hippocampus), after-
discharges can be recorded in the stimulated structure itself 
and in other areas interconnected with the challenged substrate. 
Koella et al (1976) investigated the effect of carbamazepine, 
diazepam and diphenylhydantoin on the hippocampal after-discharge 
induced by electrical stimulation of the hippocampus. 
Carbamazepine (3 mg/kg i.v.) brought about almost complete 
blockade of this limbic epileptic seizure. This effect of 
carbarnazepine was found to be superior to that of diazeparn 
and diphenyhydantoin. This could explain the therapeutic 
value of carbamazepine in temporal lobe seizures. 
Holm et al (1970) identified a rather specific action of 
carbarnazepine (20 mg/kg i.p., 6-9 µg/ml) on transmission of 
impulses through the nucleus ventralis anterior of the thalamus. 
This may be significant since the nucleus ventralis anterior has 
been implicated in the generation and spread of seizure 
discharge (Julien and Hollister 1975). 
At the spinal level, Krupp (1969) and Theobald (1970) 
found that intravenous doses of carbarnazepine (20 mg/kg) 
significantly reduced post-tetanic potentiation (PTP), but 
such effect was much less reduced at therapeutic doses (10 
mg/kg). These findings were confirmed by Julien and Hollister 
(1975) who found that PTP could be blocked at doses above the 
therapeutic range in non-anaesthetized spinal cats. 
Carbamazepine has also been shown to depress synaptic 
transmission in the spinal trigeminal nucleus. This action 
could explain its therapeutic effectiveness in trigeminal 
neuralgia (Fromm and Killian 1967). 
1.3.7.3. Membrane effects 
Schauf et al (1974) showed that carbarnazepine at a 
concentration of 0,5 mM decreased the sodium and potassium 
conductances by 50% and 40%, respectively, in voltage-clamped 
Myxicola giant axons. In addition, membrane leakage conductance 
was reduced and the membrane was reversibly depolarised by 
0-10 mv. There was little or no effect of carbamazepine on 
the time constants for sodium activation or inactivation or 
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potassium activation. 
This behaviour is in contrast to that reported by 
Lipicky et al (1972) for diphenylhydantoin which was shown 
to have a relatively specific inhibitory effect on sodium 
conductance in squid axons. 
The anticonvulsant activity of carbamazepine could 
therefore be explained by its ability to depress excitability 
rather than a highly specific effect on membrane component. 
1.3.7.4. Biochemical effects 
Garnma-aminobutyric acid 
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It has been shown that inhibition of the enzyme responsible 
for the synthesis of garnma-aminobutyric acid (GABA) or an 
action at postsynaptic sites to block GABA inhibitory action, 
leads to generalised seizures (Wood 1975; Meldrum 1975). 
Therefore it may be suggested that anticonvulsant drugs 
exert their therapeutic effects by raising the level of GABA 
in the central nervous system. 
Post et al (1980) reported on a study carried out to 
assess the effects of carbamazepine on GABA metabolism. Nine 
patients with manic depressive illness were studied. GABA 
levels were measured in cerebrospinal fluid (CSF) before and 
during treatment with carbamazepine. The dose of carbama-
zepine ranged from 800-1 600 mg per day giving blood levels 
of 8-12 µg per ml. Compared to medication free values, GABA 
levels in CSF were not significantly altered by an average 
of 30 days' treatment with carbamazepine. Therefore it 
appears that carbamazepine does not have a major effect on 
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brain GABA as a mechanism of its anticonvulsant action. 
i.'loradrenaline 
Purdy et al (1977) investigated the effect of carbamazepine 
on the uptake and release of tritiated noradrenaline ( 3H-NA) . 
At concentrations in the therapeutic range (l0- 5M), it was 
found that carbamazepine exhibited an 18i inhibition of 3H-NA 
uptake in rabbit brain synaptosomes in the absence of effects 
on transmitter release. From a comparison of carbamazepine 
with imipramine, the authors concluded that the observed 
effects of carbamazepine were insufficient to account for the 
anticonvulsant action of the drug but the inhibition of the 
uptake at 10-SM could perhaps explain carbarnazepine's analgesic 
action. 
Cyclic 3 1 5 1 -adenosine monophosphate (cAMP) 
The cAMP content of cortical slices incubated in vitro 
were increased by the convulsant action of pentylenetetrazol 
(Lewin et al 1970), by electrical stimulation (Kakiuchi et al 
1969), and by ouabain (Shimuzu et al 1970), and adenosine 
(Sattin and Rall 1970), both of which are epileptogenic when 
injected into the cortex. cAMP has also been shown to produce 
seizures when injected intraventricularly (Gessa et al 1970), 
and epileptiform discharge when applied to the surface of the 
cerebral cortex (Walker et al 1975). 
Lewin and Bleck (1977) reported on a study carried out 
to investigate the effect of carbarnazepine, phenytoin and 
phenobarbitone on the cAMP accumulation in rat cortical 
slices. 
Carbamazepine (1 mM) and phenytoin (0,3 mM) inhibited 
the increase in cAMP produced by ouabain. Carbamazepine also 
antagonised the action of adenosine stimulation of cAMP 
accumulation whereas phenytoin did not. Both carbamazepine 
and phenobarbitone inhibited cAMP accumulation produced by 
noradrenaline. Phenytoin had no effect. 
The authors concluded that if cAMP played a role in 
epileptogenesis, then inhibition of cAMP accumulation may 
well explain the mechanism of action of anticonvulsant drugs. 
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CHAPTER TWO 
PATIENTS AND METHODS 
CHAPTER TWO 
2.1. Patient selection 
A total of 23 epileptic patients took part in the study 
(12 males and 11 females). All patients had an established 
diagnosis of either generalised epilepsy (tonic-clonic 
seizures) or partial epilepsy (with complex symptomatology). 
The patients were divided into two groups according to 
the frequency of their seizures: 
RESPONDERS: Those patients who had no seizures in the month 
prior to entry into the study. 
NON-RESPONDERS: Those patients who had at least one seizure 
a week in the month prior to entry into the study. 
Compliance with medication was judged by the following 
criteria: (i) history and confirmation by random blood sampling 
and (ii) residence in an institution with documented ingestion 
by trained staff. It was also established that all patients 
had been receiving carbamazepine for not less than a month 
either alone or in combination with other anticonvulsants. 
This was done to ensure steady state levels of the drug in 
plasma. Furthermore, confirmation of therapeutic levels of 
carbamazepine in sera from non-responders was a condition of 
selection for the study. 
Full clinical details appear in Tables 1 and 2 for 
• 
responders and non-responders respectively. 
Prior to conunencement of the study the following base-
line parameters were recorded in all patients: 
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(a) Electroencephalogram (EEG) 
(b) Routine "12-channel analysis" for biochemical parameters 
(c) Blood count 
In addition, a Venereal Research Laboratory Test (VDRL) 
and computer-assisted tomography (CT-Scan) were carried out 
in certain patients not responding to therapy if the 
neurologists thought it warranted. 
Details of all the above tests appear in the Appendix 
section. 
2.2. Medication 
All patients in this study received carbamazepine 
(LABETHICA) tablets of 200 mg. 
The dose (mg/day) of carbamazepine and other concurrent 
medication appears in Tables 3 and 4 for responders and non-
responders respectively. 
2.3. Blood and Cerebrospinal Fluid Sampling (CSF) 
In all patients studied, serum concentrations of 
carbamazepine, and its epoxy and dihydroxy metabolites were 
investigated by taking blood samples every two hours between 
8 a.m. and 6 p.m. The first sample was taken just before the 
morning dose of carbamazepine. The dosage (mg/day) and the 
dosage interval were not altered in any of the patients. 
CSF samples were taken only from the non-responders, 
at the discretion of the neurologist. Full consent was 
obtained from the patient before sampling. Serum and CSF 
samples were stored at -2ooc until analysis. 
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2.4. Side effects 
Assessment of the side effects of carbamazepine that 
occurred between 8 a.m. and 6 p.m. were made; full details 
appear in the Results section. 
2.5. Length of period of observation 
At the discretion of the neurologist, certain of the 
non-responders were hospitalised for a period of one to two 
weeks in order to find a drug regimen that would improve 
their seizure frequency before being discharged. 
Responders were discharged after the last blood sample 
had been taken. 
2.6. Location 
The clinical investigations were carried out either at 
the Neurology Department at Groote Schuur Hospital (GSH), 
Cape Town, or at Valkenberg Mental Hospital, Cape Town. 
The assay of carbamazepine and its metabolites was 
carried out at the Pharmacology Department, University of 
Cape Town Medical School. 
2.7. Ethical control of the study 
The study was only initiated after the approval of the 
Ethical Review Committee of the University of Cape Town 
Medical School. 
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2.8. Analytical Methodology 
2.8.1. Introduction 
The use of fluorimetry in combination with thin-layer 
chromatography,for the determination of carbamazepine and 
metabolites, was first reported by Scheiffart et al (1966). 
These authors applied biological fluids (CSF, plasma, urine, 
bile) or their dichloroethane extracts to silica plates, which 
were developed with carbon tetrachloride: methanol: :7:1. 
Under ultraviolet light localised spots were scraped and 
eluted with 70% perchloric acid followed by heating at 1200c 
for 20 minutes. The fluorescence that developed in the eluate 
by this treatment was determined with a fluorescence spectro-
meter using an excitation wavelength of 358 nm and an emission 
wavelength of 498 nm. The concentration of carbamazepine was 
calculated from a calibration curve. 
A similar but rather less tedious procedure was described 
by Christiansen (1973). 10 µl of diluted plasma was applied 
directly to silica plates. The chromatograms were developed 
(solvents: benzene: dioxane: ethanol: 25% NH 40H: :5:4:1:1), 
dried, dipped into perchloric acid reagent (70% HCl0 4 12 ml, 
ethanol 150 ml, H20 130 ml), and then heated at 108°c for 8 
minutes. The fluorescence was measured in situ by direct 
scanning of spots at 498 nm with a fluorescence densitometer 
(Vitatron TLD 100 flying spot scanner) using an excitation 
wavelength of 366 nm. A calibration curve was made with 
the standards. 
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Meilink (1974) applied a dichloroethane extract onto 
thin layer plates which were then developed in ethyl acetate. 
The spots were scraped, eluted and induction of fluorescence 
of carbamazepine and its metabolites carried out by use of 
ammonium-eerie sulphate and phosphoric acid reagent. Measure-
ment was made with a fluorescence spectrometer; the excitation 
wavelength was 400 to 408 nm and the emission wavelength was 
475 nm to 480 nm. Cyproheptadine, imiprarnine, protrytaline 
and quinine, among others, were found to interfere with this 
method. 
The method used in this study is based on that of Hundt 
and Clark (1975). In this method carbamazepine and 
metabolites were determined simultaneously, only 2 µl of 
serum or CSF being required for a duplicate determination 
and no extraction procedure being involved. The separated 
spots (developing solvent was ethyl acetate: benzene: 
methanol: :5:4:1) were converted into fluorescent compounds 
by exposing the plates to hydrogen chloride gas for 5 minutes 
and then to ultraviolet radiation from a mercury lamp. The 
fluorescence was measured quantitatively using a spectro-
fluorimeter (Perkin-Elmer MPF3) equipped with a thin-layer 
chromatograph scanning attachment. Excitation wavelength 
was 354 nm, emission wavelength 486 nm and emission filter 
430 nm. A calibration curve was constructed from standards. 
47 
2.8.2. Experimental 
2.8.2.1. Reagents 
Carbamazepine, 10,11-epoxy-carbamazepine and 10,ll-
dihydro-10,11-dihydroxy-carbamazepine were obtained from 
Ciba-Geigy, Johannesburg, South Africa. Benzene, ethyl 
acetate, methanol, concentrated sulphuric acid and concentrated 
hydrochloric acid were guaranteed reagent grade (Analar, B.D.H. 
Chemicals, Poole, England). 
2.8.2.2. Apparatus 
A Zeiss KM3 Chromatogram Spectrophotometer was used to 
measure the fluorescence of the spots on the thin layer plates. 
The following operating conditions were used: 
(i) INDICATOR UNIT: 
Mode selector set to "R" 
Recording mode selector to KOMP F 
Damping switch set to "l" 
High-voltage selector to step 1 
(ii) RECORDER UNIT: 
Chart paper speed 5 cm/min 
Scanning speed 100 mm/min 
Measuring range lV 
(iii) ILLUMINATOR AND MONOCHROMATOR: 
Mercury source was provided 
Exciting wavelength set to 257 ~m 
Slit width set to 0,5 mm 
4.3 
ILLUMINATOR AND MONOCHROMATOR: 
Barrier filter FL46 was used 
Slip-in diaphragm 3,5 nun was used 
The amplification was adjusted to obtain approximately 
90% full-scale deflection on the recorder when the strongest 
spot in the chromatogram was being scanned. 
The other apparatus used consisted of silica gel 60 TLC 
plates, dimensions 10 x 20 cm (Merck), a sample applicator for 
thin layer chromatography (EVA CHROM), a 2 µl capillary 
(Minicaps), a universal UV lamp, type 29000 (Camag), and a 
Sartorius electronic microbalance. (See Appendix F for 
suppliers.) 
2.8.2.3. Stock solutions 
A single stock solution containing 1 mg of carbamazepine, 
0,33 mg of 10,11-epoxy-carbamazepine and 0,33 mg of 10,ll-
dihydro-10,11-dihydroxy-carbamazepine in 10 ml absolute 
methanol was prepared as follows. The reagents were weighed 
separately on a Sartorius electronic microbalance and solutions 
made up with methanol to contain 3 mg of carbamazepine, 1 mg 
of 10,11-epoxy-carbamazepine and 1 mg of 10,11-dihydro-10,ll-
dihydroxy-carbamazepine per 10 ml of solution. Equal volumes 
of these solutions were then added together so as to give the 
final stock solution. 
Final stock solution used for CSF standards contained 
0,587 mg of carbamazepine, 0,336 mg of 10,11-epoxy-carbamazepine 
and 0,253 mg of 10,ll-dihydro-10,11-dihydroxy-carbamazepine 
in 10 ml of absolute methanol. 
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2.8.2.4. Standard Solutions 
Four standard solutions were prepared by adding with 
micropipettes 20, 40, 80 and 120 µl of the stock solution in 
each instance to sample tubes. The solvent was evaporated 
off, and the residue then re-dissolved in 1 ml serum/CSP so 
as to obtain the standard serum/CSP solutions. 
2.8.2.5. Spotting the Plates 
To 200 µl of serum (patient or standard) was added 200 µl 
of distilled water. After thoroughly mixing on a vortex mixer 
exactly 2 µl of the serum solution was then spotted on the 
plate in a single, smooth application. In this fashion, 
twenty-two spots with unknown serum and standard serum 
alternating in duplicate were applied to a single 10 x 20 cm 
plate. This corresponded to six unknown serum samples being 
processed in duplicate. 2 µl of CSF (patient or standard) 
was applied directly to the plate without dilution. 
2.8.2.6. Chromatography 
The eluent used was ethylacetate benzene : methanol:: 
5:4:1. The development was carried out in an unsaturated tank 
up to a height of 8 cm; the elution time was ca. 20 minutes. 
After drying them briefly with a hairdryer, the plates 
were dried at 100°c for 5 minutes and then exposed for 15 
minutes to hydrogen chloride gas generated in a chromatographic 
tank by pipetting 3 ml of concentrated hydrochloric acid into 
20 ml of concentrated sulphuric acid in a small beaker in the 
tank. Immediately after exposure to hydrogen chloride gas, 
the plates were irradiated for 1 hour with ultra-violet light 
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obtained from an unfiltered mercury lamp (254 nm). This 
procedure converted carbarnazepine and its metabolites into 
fluorescent compounds that could be measured directly and 
quantitatively with the Zeiss KM3 chromatogram spectrophoto-
meter. Each series of spots corresponding to an applied sample 
was scanned in the direction of solvent flow. 
From the peak heights obtained for the known concentrations 
of carbamazepine and metabolites, an equation of the best 
straight-line fit was obtained by linear regression analysis, 
and this equation was used in the calculation of the concen-
trations of carbamazepine and metabolites in unknown sera and 
CSFs. 
Figs. 11 and 12 represent part of a chromatogram showing 
the peaks obtained for standard serum and CSF containing the 
indicated amounts of carbamazepine and its two metabolites. 
2.8.2.7. Validation 
Prior to the patient samples being assayed, four serum 
and CSF samples were spiked at each concentration in order to 
ensure reproducibility. From the regression coefficients 
obtained (Tables 5 - 10), it can be seen that this ratio is 
linear over the concentration range used. The coefficient 
of variation for carbarnazepine standards, in serum and CSF, 
did not exceed 3% at each concentration and for the metabolites 
the coefficient of variation was within 8% at each concentration 
employed. 
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If the peak heights of duplicate samples did not agree 
to within 10% the samples were re-assayed. 
Furthermore, a control serum (EMIT-AED, SYVA) was run 
with the assay and if the carbamazepine concentration did 
not agree to within 10% of the actual value, the standards 
were recalibrated. 
Control serum for the metabolites and control CSF for 
carbamazepine and metabolites were also prepared and if 
agreement in concentration between the calculated and actual 
value did not agree to within 10%, the standards were re-
calibrated. Calibration curves for carbamazepine and 
metabolites in serum are shown in figs. 6-8~ for CSF in 
figs. 9-11. 
2.8.2.8. Specificity 
Hundt and Clark (1975) in their paper reported that sera 
of a large number of patients receiving a diversity of drugs 
were chromatographed and treated as already described. In 
no instance was any spot found that could possibly interfere 
in the assay of carbamazepine or the two metabolites. 
In this study blank serum samples were run with each 
assay. No interfering peaks could be detected. 
The Pharmacology Department, Medical School, University 
of Cape Town, employs this method for the routine assay of 
carbamazepine. Serum samples from patients, not on carbamaze-
pine therapy, have been shown to give no peaks when the 
chromatographic plates are scanned either on the Perkin-Elmer 
MPF3 spectrofluorimeter or the Zeiss KM3 spectrophotometer. 
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2.8.2.9. Sensitivity 
According to Hundt and Clark (1975), the lowest 
demonstrable concentration of carbamazepine in serum was 
O,l µg/ml, while those for each metabolite corresponded to 
0,05 µg/ml. 
In this study no patients had carbamazepine concen-
trations less than 2 µg/ml and metabolite concentrations 
less than O,l µg/ml. 
2.9. Calculation of Area under the Curve (AUC) 
The area under the plasma concentration/time curve for 
carbamazepine (AUCCBZ), 10,11-epoxy-carbamazepine (AUCEPOXY) 
and 10,ll-dihydro-10,11-diydroxy-carbamazepine (AUCDI-OH) 
were calculated by making use of the trapezoidal rule (see 
Appendix E). 
2.10. Statistical analysis 
The Mann-Whitney U test was used for the comparison of 
data between responders and non-responders. The Mann-Whitney 
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is one of the most powerful non-parametric tests and was employed 
because the distribution of parameters from the assay and 
patient population was not expected to be normal. The power 
efficiency of the test is close to 95 per cent (Mood 1954). 
Other statistical testsused included the Spearman rank 
correlation test, the randomization test for two independent 
samples and the Student's t distribution. 
above tests appear in the Appendix.) 
(Details of all the 
""' 
L{) 
TA
BLE 
1
: 
CLIN
ICA
L 
DATA 
OF 
AGE 
W
EIGHT 
IN
IT
IA
L
S 
SEX 
(YRS) 
(KG) 
AvA 
F 
20 
70 
V
P 
F 
35 
50 
R
I 
F 
18 
52 
KS 
M
 
27 
76 
JA
 
M
 
JS 
75 
JT
 
M
 
21 
62 
RT 
M
 
JJ 
SJ 
DN 
M
 
27 
65 
DH 
M
 
li2 
72 
s
s
 
M
 
34 
78 
DR 
F 
32 
60 
MA 
M
 
23 
62 
G
E: 
G
en
eralised
 
ep
ilep
sy
 
PE
: 
P
a
rtia
l 
ep
ilep
sy
 
GM
: 
G
rand-m
al 
s
eizu
res 
PM
: 
P
sychom
otor 
s
eizu
res 
M
: 
M
ale 
F
: 
F
em
ale 
W
: 
W
hite 
C: 
C
oloured 
E
PIL
E
PT
IC
 
RESPO
N
D
ERS. 
D
U
RA
TION 
OF 
FREQUENCY 
EPILEPSY
 
TY
PE 
OF 
TY
PE 
OF 
OF 
SEIZU
RE 
RACE 
(YRS) 
E
PIL
E
PSY
 
SEIZU
RE 
(PER M
ONTH) 
w
 
9 
GE 
GM 
N
IL 
C 
10 
GE 
GM 
"
 
C 
6 
GE 
GM 
"
 
C 
11 
PE 
PM
 
"
 
c
· 
14 
PE 
PM
 
"
 
C 
5 
PE 
PM
 
"
 
w
 
27 
GE 
GM
 
II 
w
 
14 
GE 
GM 
II 
w
 
11 
GE 
GM 
II 
w
 
10 
PE 
PM
 
II 
w
 
28 
PE 
PM
 
II 
w
 
J 
PE 
PM
 
II 
U
r 
l!) 
TA
BLE 
2
: 
C
LIN
IC
A
L 
DATA 
OF 
AGE 
W
EIGHT 
IN
IT
IA
L
S 
SEX
 
(YRS) 
(KG) 
M
F 
F 
J2 
51 
BG 
F 
JJ 
SJ 
G
P 
F 
20 
52 
RA 
M
 
17 
74 
M
C 
M
 
45 
68 
QJ 
F 
18 
4
J 
M
B 
M
 
19 
54 
JN
 
F 
20 
49 
cc 
F 
16 
41 
RC 
M
 
44 
75 
SH 
F 
10 
40 
G
E: 
G
en
eralised
 
ep
ilep
sy
 
PE
: 
P
a
rtia
l 
ep
ilep
sy
 
GM
: 
G
rand-m
al 
s
eizu
res 
PM
: 
P
sychom
otor 
s
eizu
res 
M
: 
M
ale 
F
: 
F
em
ale 
W
: 
W
hite 
C: 
C
oloured 
E
PIL
E
PT
IC
 
N
O
N
-RESPO
N
D
ERS. 
D
U
RA
TIO
N
 
OF 
FREQUENCY 
E
PIL
E
PSY
 
TY
PE 
OF 
TY
PE 
OF 
OF 
SEIZU
R
E 
RACE 
(YRS) 
E
PIL
E
PSY
 
SEIZU
R
E 
(PER M
ONTH) 
w
 
14 
PE 
PM
 
8 
w
 
24 
PE 
PM
 
8 
C 
11 
GE 
GM
 
10 
w
 
5 
PE 
PM
 
7 
w
 
20 
PE 
PM
 
12 
C 
13 
GE 
GM 
lJ
 
C 
4 
GE 
GM
 
6 
w
 
18 
GE 
GM
 
10 
C 
9 
GE 
GM 
6 
C 
12 
GE 
GM 
6 
w
 
5 
PE 
PM
 
6 
I.!) 
L
I) 
TA
BLE 
IN
IT
IA
L
S 
AvA 
V
P 
R
I 
KS 
JA
 
JT
 
RT 
DN 
DH 
s
s
 
BR 
MA 
J: 
M
ED
ICA
TIO
N
 
CARBAM
AZEPINE 
(mg/day) 
1 
000 
800 
400 
600 
400 
600 
600 
400 
400 
400 
1 
200 
400 
CHART 
OF 
E
PIL
E
PT
IC
 
RESPO
N
D
ERS. 
PH
ENOBARBITONE 
(mg/day) 
PH
EN
Y
TO
IN
 
(mg/day) 
JOO 
200 
CO
-M
ED
ICA
TIO
N
 
(mg/day) 
CLO
ZA
PIN
E (200) 
CLO
ZA
PIN
E (200) 
CHLORPROM
AZINE (150) 
CLO
ZA
PIN
E (200) 
FLU
PH
EN
A
ZIN
E (25) 
FLU
PH
EN
A
ZIN
E (25) 
CHLORPROM
AZINE (100) 
CLO
ZA
PIN
E ( 200) 
CHLORPROM
AZINE (700) 
ORPHENADRINE (200) 
r, 
If'\ 
TABLE 
4: 
IN
IT
IA
LS 
M
F 
BG 
GP 
RA 
MC 
QJ 
M
B 
JN
 
c
c
 
RC 
SH 
M
ED
ICA
TIO
N
 
CHART 
CARBAM
AZEP IN
E 
(mg/day) 
800 
800 
800 
800 
900 
800 
800 
1 
000 
600 
800 
600 
OF 
E
PIL
E
PT
IC
 
N
O
N
-RESPO
N
D
ERS. 
PH
ENOBARBITONE 
PH
EN
Y
TOIN 
CO
-M
ED
ICA
TIO
N
 
(mg/day) 
(mg/day) 
(mg/day) 
-
-
DOM
PERIDONE (JO) 
M
AGNESIUM
 T
R
ISILIC
A
TE 
(1 
o
o
o) 
60 
-
-
ETHOSUXIM
IDE (800) 
60 
200 
-
100 
90 
90 
-
JOO 
co 
L
f) 
TA
BLE 
5: 
V
A
LID
A
TIO
N
 
OF 
A
N
A
LY
TICA
L 
M
EAN 
EX
PECTED
 
NUM
BER 
OF 
PEAK 
CONCENTRATION 
SPIK
ED
 
H
EIG
H
T 
(µg/ml) 
SAM
PLES 
(mm) 
0 
4 
0 
2 
/4 
32,5 
4 
4 
65 
8 
/4 
lJO
,J 
12 
4 
189,5 
S
lope 
=
 1
5
,9
 
Y
 In
te
rc
ep
t 
=
 1
,0
1
 
C
o
rrelatio
n
 
c
o
e
ffic
ie
n
t (rJ 
=
 0,9996 
r 
=
 0,9992 
M
ETHOD 
FOR 
CARBAM
AZEPINE 
IN
 
SERUM
. 
C
O
EFFIC
IEN
T 
OBSERVED 
STANDARD 
V
A
RIA
TIO
N
 
CONCENTRATION 
D
EV
IA
TIO
N
 
(%) 
( µ g/m
l) 
0 
0 
o
,o
o
 
0
,58 
1
,7
8
 
1
,99 
1
,15 
1
,7
8
 
4,04 
2
,75 
2
,1
1
 
8,15 
1
,91 
1
,0
0
 
1
1
,9 
CY\ 
L
f) 
TA
BLE 
6: 
V
A
LID
A
TIO
N
 
OF 
A
N
A
LY
TICA
L 
IN
 
SERUM
. 
M
EAN 
EXPEC"'TED 
NUM
BER 
OF 
PEAK 
CONCENTRATION 
SPIK
ED
 
H
EIG
H
T 
( µg/m
l) 
SAM
PLES 
(mm) 
0 
4 
0 
0,67 
4 
J6
,J 
l,J
J
 
4 
7
4
,J 
2
,67 
4 
1
46,8 
4
,o
o
 
Ii 
2
1
7
,5 
S
lope 
=
 54,4 
Y
 In
te
rc
e
p
t 
=
 
o
,4
7
 
C
o
rrelatio
n
 
c
o
e
ffic
ie
n
t (rJ 
=
 0,9996 
r 
=
 0,9992 
M
ETHOD 
FO
R 
10, 11-EPO
X
Y
-CA
RBA
M
A
ZEP.IN
E 
C
O
EFFIC
IEN
T 
OBSERVED 
STANDARD 
V
A
R
IA
TIO
N
 
CONCENTRATION 
D
EV
IA
TIO
N
 
(%) 
(µg/m
l) 
0 
0 
0 
0
,96 
2
,64 
o
,66 
0
,50 
o
,67 
l,J6
 
2
,6
J 
1
,7
9
 
2
,69 
4
,7
2
 
2
,1
7
 
J,9
9
 
0 \..D 
TA
BLE 
2: 
V
A
LID
A
TIO
N
 
OF 
A
N
A
LY
TICA
L 
CARBAM
AZEPINE 
IN
 
SERUM
. 
M
EAN 
EX
PECTED
 
NUM
BER OF 
PEAK 
CONCENTRATION 
SPIK
ED
 
H
EIG
H
T 
UiliL'.'. m
l ) 
SAM
PLES 
(mm) 
0 
4 
0 
o
,67 
4 
1
1
 
1
,3
3
 
4 
23,5 
2
,67 
4 
4
6
,J 
4
,o
o
 
4 
68,5 
S
lope 
=
 1
7
,2
 
Y
 In
te
rc
ep
t 
=
 0,04 
C
o
rrelatio
n
 
c
o
e
ffic
ie
n
t (rJ 
=
 0,9961 
r 
=
 0,9922 
M
ETHOD 
FOR 
10,ll-D
IH
Y
D
R
0-10,11-D
IH
Y
D
R
O
X
Y
-
C
O
EFFIC
IEN
T 
OBSERVED 
STANDARD 
V
A
RIA
TIO
N
 
CONCENTRATION 
D
EV
IA
TIO
N
 
(%) 
{µ g/m
l) 
0 
0 
0 
0,71 
6,45 
o
,64 
0
,58 
2
,4
7
 
1
,36 
1
,5
0
 
J,2
3
 
2
,69 
5,25 
7
,67 
3,98 
rl 
I..O 
TA
BLE 
8
: 
V
A
LID
A
TIO
N
 
OF 
A
N
A
LY
TICAL 
M
EAN 
EX
PECTED 
NUM
BER 
OF 
PEAK 
CONCENTRATION 
SPIK
ED
 
H
EIG
H
T 
u
g
/m
1) 
SAM
PLES 
(mm) 
0 
4 
0 
1
,1
7
 
4 
2
7
,9 
2
,35 
4 
54,4 
4,69 
4 
106,8 
7
,0h 
li 
16) 
S
lope 
=
 2) 
Y
 In
te
rc
ep
t 
=
 0,21 
C
o
rrelatio
n
 
c
o
e
ffic
ie
n
t ( r J =
 0, 999l1 
r 
=
 0,9988 
M
ETHOD 
FOR 
CARBAM
AZEPINE 
IN
 
C
SF. 
C
O
EFFIC
IEN
T 
OBSERVED 
STANDARD 
V
A
RIA
TIO
N
 
CONCENTRATION 
D
EV
IA
TIO
N
 
(%) 
(µg/m
l) 
0 
0 
0 
0,85 
J,0
4
 
1
,2
0
 
1
,25 
2
,29 
2
,35 
0,96 
O, 90 
4
,6) 
4
,)2 
2
,65 
7
,07 
N
 
I.D
 
TA
BLE 
_
 
_2: 
V
A
LID
A
TIO
N
 
OF 
A
N
A
LY
TICAL 
IN
 
C
SF. 
M
EAN 
EX
PECTED 
NUM
BER 
OF 
PEAK 
CONCENTRATION 
SPIK
ED
 
H
EIG
H
T 
(µg/ml) 
SAM
PLES 
(mm) 
0 
4 
0 
o
,68 
4 
21 
1
,35 
4 
4
1
,8 
2,69 
4 
80,8 
4,04 
li 
120 
S
lope 
=
 29,6 
Y
 In
te
rc
ep
t 
=
 
o
,8
J 
C
o
rrelatio
n
 
c
o
e
ffic
ie
n
t (r) 
=
 
0,9996 
r2 
=
 0,9992 
M
ETHOD 
FOR 
10
1 11-EPO
X
Y
-CA
RBA
M
A
ZEPIN
E 
C
O
EFFIC
IEN
T 
OBSERVED 
STANDARD 
V
A
RIA
TIO
N
 
CONCENTRATION 
D
EV
IA
TIO
N
 
(%) 
(µg/ml) 
0 
0 
0 
1
,63 
7
,76 
o
,68 
0,96 
2,29 
1
,39 
0,96 
1
,19 
2,70 
0,96 
0,80 
4,01 
M
 
I.D
 
TA
BLE 
10: 
V
A
LID
A
TIO
N
 
OF 
A
N
A
LY
TICA
L 
CARBAM
AZEPINE 
IN
 
C
SF. 
M
EAN 
EX
PECTED
 
NUM
BER 
OF' 
PEAK 
CONCENTRATION 
SPIK
ED
 
H
EIG
H
T 
( µg/m
l) 
SAM
PLES 
(mm) 
0 
4 
0 
0,51 
4 
1
0
,1
 
1
,0
1
 
4 
20,4 
2
,0
J 
l-i 
J6
,J 
J,0
4
 
4 
54,o 
S
lope 
=
 1
7
,5
 
Y
 In
te
rc
ep
t 
=
 1
,06 
C
o
rrelatio
n
 
c
o
e
ffic
ie
n
t (rJ 
=
 0,9962 
r 
=
 0,9924 
M
ETHOD 
FOR 
10,ll-D
IH
Y
D
R
0-10,11-D
IH
Y
D
R
O
X
Y
-
C
O
EFFIC
IEN
T 
OBSERVED 
STANDARD 
V
A
R
IA
TIO
N
 
CONCENTRATION 
D
EV
IA
TIO
N
 
(%) 
(µg/m
l) 
0 
0 
0 
0
,85 
o
,4
3
 
0,52 
1
,2
5
 
0,63 
1
,1
0
 
1
,5
0
 
0,75 
2,01 
2
,94 
1
,4
7
 
J,0
2
 
200 
180 
160 
140 
-E 
E 
-120 
.... 
.s:: 
0) 
-Cl) 
::c 10 
6 
40 
20 
Y =15·9x + 1· 01 
r = 0·9996 
0 2 4 6 8 10 12 
Carbamazepine Concentration.lug/mlJ 
Fig. 6: Calibration curve for the determination of carbamazepine in serum. 
Co-ordinates plotted represent mean of observed valves. 
64 
22 
200 
180 
160 
140 
-E 
E 
-120 
.. 
.c: 
C) 
·-~ 10 
~ 
(U 
&_ 80 
60 
40 
65 
Y=54·4X+0·4 7 
r= 0·9996 
0 1 2 3 4 
10,11-Epoxy-Carbamazepine Concentration (ug/mlJ 
Fig. 7: Calibration curve for the determination of 10,11-Epoxy-Carbamazepine in 
Serum. Co-ordinates plotted represent mean of observ~d values. 
70 
60 
eso 
E 
-
:C40 
C) 
·-Cl) 
::c: 30 
~ 
ca 
·~20 
10 
Y=17·2X +0-04 
r == 0·9961 
1 2 3 
10, 11-D ihydro -10, 11-D ihydroxy- Carbamazepine 
Concentration l.ug/ml J 
66 
Fig. 8: Calibration curve for the determination of 10,11-Dihydro-10,ll-Dihydroxy-
Carbamazepine in serum. Co-ordinates plotted represent mean of observed 
values. 
4 
18 
160 
140 
-12 E 
E 
-
..,10 
.t= 
C, 
·-Q) 
:c 8 
~ 
ca 
Q) 
C. 
20 
Y=23x+0·21 
r =0·9994 
0 1 2 3 4 5 6 7 
Carbamazepine Concentration (JJg/mlJ 
Fig. 9: Calibration curve for the determination of carbamazepine in CSF. 
Co-ordinates plotted represent mean of observed values. 
67 
8 
140 
120 
100 
8 
-E 
_§ 60 
..., 
.c 
0) 
·-G) 40 ~ 
~ 
ca 
G) 20 a. 
0 
Y= 29 ·6x +0·83 
r == 0-9996 
1 2 3 
68 
10,11-Epoxy-Carbamazepine Concentration tug/ml J 
4 
Fig. 10. Calibration curve for the determination of 10,11-epoxy-carbamazepine in CSF. Co-ordinates plotted represent mean of observed valves. 
3 
-E 
.§3 
5 
Y=17·5x+1·06 
r - 08962 
69 
Q ..... ____ ...._ ____ __.. _____ ..,_ ___ ____. 
1 2 
10,11-Dihydro -10,11-Dihydroxy-Car bamazep ine 
Concentration IJJ9 / ml J 
Fig. 11: Calibration curve for the detennination of 10,ll-Dihydro-10,11-Dihydroxy-
Carbamazepine in CSF. Co-ordinates plotted represent mean of observed 
values. 
4ug/m11JII 
1~/ml III 
2· 67ug/ml IIII 
l.19/ml(I 
l:mJ 
4..ug/ml 
1·33lJ9/mlOIJ 
4ug/m1II1 
1ml 
2,76 
ug/ml 
lmJ 
1·33 
ug/ml 
Standards 
0.67µg/mdlII 
2ug/m1(I) 
IIIIJ 
0·67 µg/ml 
III 
1ml 
111 
[I) 
Iii 
(1lIJ 
NR R 
Fig. 12: Chromatogram of different amounts of carbamazepine and its two 
metabolites in serum. (I) carbamazepine; (II) 10,11-Epoxy-
carbamazepine (III) 10,11-Dihydro-10,11-Dihydroxy-Carbamazepine; 
(NR) typical non-responder; (R) typical responder. 
70 
IIIl4.04.ug/m1 
!It,.04.ug/ml 
3·04 
.ug/ml 
I I 
!Itl2· 69.ug/ml 
2-03 
.uriml 
(114·69.ug/ml 
llU1·35.ug/ml 
1·01 1:IJ2·35ugm,I J.Jir 
Standards N R 
Fig. 13 Chromatogram of different amounts of carbamazepine and its two 
metabolites in CSF. (I) Carbamazepine; (In 10,11-Epoxy-
Carbamazepine (III) 10,11-Dihydro-10,ll-Dihydroxy-Carbamazepine; 
(NR) Non-responder. 
71 
72 
CHAPTER THREE 
RESULTS 
CHAPTER THREE 
3.1. Results 
3.1.l. Side-effects 
Only 6 of the 23 patients in the study complained of 
side-effects; 3 patients in each of the responder and non-
responder groups. 
Headaches, nausea and drowsiness were the most 
frequently mentioned complaints. Table 11 gives details 
of carbamazepine and metabolite concentrations at which 
these side-effects occurred. In the responder group, the 
mean levels of carbarnazepine and its epoxy and dihydroxy 
metabolites were 8,18, 1,33 and 2,53 µg/ml in patients with 
side-effects, compared with 6,11, 0,82 and 2,17 µg/ml in 
patients without side-effects. In the non-responder group, 
the mean levels of carbamazepine and its epoxy and dihydroxy 
metabolites were 8,99, 2,04 and 5,31 µg/ml in patients with 
side-effects, compared with 8,41, 1,73 and 5,19 µg/ml in 
patients without side-effects. 
The randomization test for two independent samples 
showed that these results are not statistically 
significant. 
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3. 1. 2 . Area under the curve (AUC) of carbamazepine and 
metabolites 
In this study all patients had been taking carbarnazepine 
for not less than a month before serum samples were 
collected. It can therefore be assumed that the steady-
state concentrations had been reached. The AUC was there-
fore chosen as the parameter that would best give the overall 
picture of the concentrations of carbarnazepine and its 
metabolites in plasma. Tables 12 and 13 give details of 
the AUC of carbamazepine and its epoxy and dihydroxy 
metabolites for responders and non-responders, respectively. 
This was calculated from the concentration/time profiles as 
illustrated by figs. 14 and 15 for responders and figs. 16 
and 17 for non-responders. Tables 19 and 20 give details 
of the concentrations of carbarnazepine and its metabolites 
between 8 a.m. and 6 p.m. in responders and non-responders, 
respectively. 
In performing the Mann-Whitney U test on these results, 
it was found that there was no significant difference in the 
AUCCBZ between responders and non-responders. However, 
the AUCDI-OH was significantly higher in the non-responders 
(P <0,002). The AUCEPOXY was also higher in non-responders 
but at a lower significance level (P <0,02). 
The same results are obtained by using mean concen-
trations of carbarnazepine and metabolites (Tables 14 and 15). 
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3. L 3. Polypharmacy versus carbarnazepine monotherapy 
Eight patients in this study were taking carbarnazepine 
concomitantly with either phenobarbitone and/or phenytoin1 
6 patients were from the non-responder group and 2 from the 
responder group. As these drugs are known to induce liver 
enzymes, a comparison of the AUC of the dihydroxy and epoxy 
metabolites was made between these patients and the 8 that 
were on carbarnazepine monotherapy. No significant difference 
in metabolite concentration could be demonstrated between the 
two groups, presumably because auto-induction of metabolism 
had already proceeded to a limit. 
Phenothiazines are a class of drugs that have the ability 
to inhibit the cytochrome P450 enzymes of the liver. This 
effect has been clearly demonstrated for thioridazine on the 
metabolism of phenytoin (Vincent 1980). 
In the responder group, 7 out of the 12 patients were 
taking phenothiazines concomitantly with carbarnazepine. 
However, no significant difference in the concentrations of 
the dihydroxy and epoxy metabolites could be demons·trated 
between these patients and those on carbarnazepine monotherapy 
in that group. 
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3.1.4. Cerebrospinal fluid (CSF) concentrations of 
carbamazepine and metabolites 
It was possible to obtain CSF samples from 7 out of the 
11 patients classified as non-responders. Table 16 gives 
details of CSF and serum concentrations (obtained within the 
same time interval) for carbamazepine and metabolites. The 
ratio of CSP/serum gives a mean (±SD) free fraction for 
carbamazepine of 0,25±0,05; 0,62±0,13 for the 10,11-epoxy-
carbamazepine and 0,41±0,08 for the 10,ll-dihydro-10,11-
dihydroxy-carbamazepine. These values are in agreement with 
those obtained by Schneider and Berenguer (1975). It is 
interesting to note that the mean (±SD)- ratio of 10,11-epoxy-
carbamazepine to carbamazepine in CSF is 0,55 (±0,13) whilst 
the mean (±SD) ratio of 10,ll-dihydro-10,11-dihydroxy-
carbamazepine is as high as 1,17 (±0,36). For ethical 
reasons, it was not possible to obtain CSF from the patients 
in the responder group. As a result, to what extent these 
findings are significant is not known. 
3.1.5. Fluctuations in serum levels of carbamazepine 
Two to four hours after each administration, a more or 
less pronounced peak in the concentration of carbamazepine 
in blood was attained in every patient. Tables 17 and 18 
give a detailed review of the difference between minimum and 
maximum carbamazepine concentrations occurring in the course 
of the day between 8 a.m. and 6 p.m. in responders and non-
responders, respectively. 
In the responder group, the mean (±SD) minimum 
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concentration was 4,82±1,68 µg/ml, whereas the mean (±SD) 
maximum concentration was 6,86±1,86 µg/ml. In the non-
responder group, on the other hand, the mean (±SD) minimum 
concentration of carbamazepine was 5,71±2,06 µg/ml and mean 
(±SD) maximum concentration was 8,78±2,81 µg/ml. Average 
fluctuations from the mean (±SD) were 36±20% and 45±13% in 
responders and non-responders, respectively. Figs. 14 and 15 
and figs. 16 and 17 are graphical representations of these 
fluctuations. 
3.1.6. Dose of carbamazepine 
Although no significant difference could be demonstrated 
in the between responders and non-responders, 
the patients in the non-responder group had a higher mean 
(±SD) oral intake of carbamazepine 791(±114)mg/day compared 
with a mean (±SD) of 600(±270)mg/day for patients in the 
responder group (P <0,05). The significance of this will be 
discussed later. 
3.1.7. Correlation between the plasma level of carbamazepine 
and its metabolites 
The relationship between the mean concentration of carba-
mazepine and its epoxy and dihydroxy metabolites are shown in 
figs. 18 to 21. 
The correlation coefficient (r) of 0,76 (P <0,01) and 
0,88 (P <0,001) in responders and non-responders, respectively, 
indicates that a strong positive correlation exists between 
the concentration of 10,11-epoxy-carbamazepine and the 
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concentration of carbamazepine in plasma of the patients in 
this study. However, in interpreting these correlations, it 
must be noted that the intercepts of the regression lines do 
not pass through zero. This means that there may 
not necessarily be a linear relationship between the concen-
tration of the epoxy metabolite and the drug in plasma. 
In the case of the 10,ll-dihydro-10,11-dihydroxy-
carbamazepine, again a strong positive correlation exists 
between the concentration of this metabolite and the concen-
tration of carbamazepine; correlation coefficient (r) is 0,81 
(P<0,01) and 0,85 (P<0,001) in responders and non-responders, 
respectively. The intercepts of the regression lines pass 
through zero and therefore a linear relationship between this 
metabolite and the drug may exist. However, since there may not 
be linear relationship between the epoxy metabolite and· 
carbamazepine, it is unlikely that a change in the plasma 
concentration of carbamazepine will result in a proportional 
change in the concentration of the dihydroxy metabolite in 
plasma. 
3. 1. 8. Correlation between the plasma level of 10,11-epoxy-
carbarnazepine and 10,ll-dihydro-10,11-dihydroxy-
carbarnazepine 
The relationship between the concentration of 10,11-epoxy-
carbarnazepine and 10,ll-dihydro-10,11-dihydroxy-carbarnazepine 
shown in figs. 22 and 23 for responders and non-responders, 
respectively. 
The dihydroxy metabolite is formed by an enzymatic 
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cleavage of the epoxide ring (Faigle 1975). In both responders 
and non-responders a positive correlation exists between the 
dihydroxy and epoxy metabolite concentration in plasma; 
correlation coefficient (r) is 0,78 (P<0,01) and 0,79 (P<0,01) 
in responders and non-responders, respectively. Since the 
intercepts of the regression lines do not pass through zero, 
it is unlikely that a change in the plasma level of the epoxy 
metabolite will result in a proportional change in the 
concentration of the dihydroxy metabolite in plasma. 
3.1.9. The Spearman Rank Correlation Test 
In view of the apparent non-linearity of the correlations, 
the Spearman rank correlation test was felt to be more 
appropriate to determine the relationship between carbarnazepine 
and its metabolites and the relationship between the epoxy and 
dihydroxy metabolites. 
Responders Non-responders 
EPOXY/CBZ r = 0,76, p <0,01 rs = 0,86, p <0,001 s 
DI-OH/CBZ rs = 0,85, p <0,001 r = 0,84, p <0,01 s 
DI-OH/EPOXY r = 0,80, p <0,01 r = 0,77, p <0,01 s s 
(CBZ: carbarnazepine; EPOXY: 10,11-epoxy-carbarnazepine; 
DI-OH: 10,ll-dihydro-10,11-dihydroxy-carbarnazepine; 
rs: Spearman rank correlation coefficient.) 
This non-parametric test shows unequivocally that there 
• 
is a positive correlation between the concentration of 
carbarnazepine and the concentration of its metabolites in 
plasma. 
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3.1.10. Summary of results 
The Mann-Whitney U test was used for all statistical 
analyses summarized below: 
( l) 
( 2) 
(3) 
= 11 non-responders; = 12 responders. 
Parameter 
AUCCBZ 
AUCDI-OH-CBZ 
AUCEPOXY 
Dose (mg/day) 
Results 
n.s.* 
Higher in non-responders 
(P <0,002) 
Higher in non-responders 
(P <0,02) 
Higher in non-responders 
(P <O ,05) 
= 
= 
8 patients on phenobarbitone and/or phenytoin; 
8 patients on carbamazepine monotherapy. 
AUCDI-OH 
AUCEPOXY 
nl = 5 patients 
(responder 
n2 = 7 patients 
(responder 
AUCDI-OH 
AUCEPOXY 
n.s.* 
on carbamazepine mono therapy 
group only); 
on phenothiazinesplus carbamazepine 
group only) . 
n.s.* 
* n.s. = not significant at the 5% level. 
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TABLE 12: INDIVIDUAL VALUES OF AREA UNDER THE CURVE (AUC) 
(µg/ml. hr) FOR CARBAMAZEPINE AND METABOLITES AND THEIR 
RESPECTIVE RATIOS IN EPILEPTIC RESPONDERS. 
EPOXY DI-OH ___ DI-OH 
INITIALS CBZ EPOXY DI-OH CBZ CBZ_ EPOXY 
AvA 75,65 10,33 27,48 0, 14 0,36 2,66 
VP 50,70 5,93 21 , 2 5 0, 13 0,42 3,58 
RI 88,58 24, 16 33,90 0,27 0,38 1 , 4 0 
KS 58,75 11 , 1 0 33,35 0, 19 0,57 3,00 
JA 4 2, 11 5,63 1 8 , 1 2 0, 1 3 0,43 3,22 
JT 80,02 11 , 5 3 29,34 0, 14 0,37 2,54 
RT 66,47 9,86 23,75 0, 1 5 0,36 2,40 
DN 66,48 _9,22 19,58 0, 14 0,29 2, 1 2 
DH 41 , 2 9 5,12 1 6, 1 2 0, 1 2 0,39 3, 1 5 
ss 41 , 2 2 5,64 11 , 8 5 0, 1 4 0,29 2, 1 0 
BR 62,85 4,76 20,68 0,08 0,33 4,34 
MA 44,63 8,69 18,45 0,19 0,41 2, 1 2 
CBZ: Carbamazepine 
EPOXY: 10,11-epoxy-carbamazepine 
DI-OH: 10,11-dihydro-10,11-dihydroxy-carbamazepine 
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TABLE 13: INDIVIDUAL VALUES OF AREA UNDER THE CURVE (AUC) 
(µg/ml.hr) FOR CARBAMAZEPINE AND METABOLITES AND THEIR 
RESPECTIVE RATIOS IN EPILEPTIC NON-RESPONDERS. 
EPOXY DI-OH DI-OH 
INITIALS CBZ EPOXY DI-OH CBZ CBZ EPOXY 
MF 48,46 8,80 46,02 0, 1 8 0,95 5,23 
BG 81 , 5 0 13,98 47,20 0, 1 7 0,58 3,38 
GP 79,03 19,89 63,23 0,25 0,80 3, 1 8 
RA 58,66 12,24 39,28 0, 21 0,67 3, 21 
MC 97,24 22,76 71 , 7 0 0,23 0,74 3. 1 5 
QJ 82,84 20,34 73,36 0,25 0,89 3,60 
MB 74,51 16,95 42,94 0,23 0,58 2,53 
JN 116,96 35,26 79,28 0,30 0,68 2,25 
cc 43,32 9,46 32,01 0,22 0,74 3,38 
RC 38,52 12,93 28,18 0,34 0,73 2, 1 8 
SH 76,97 13,37 59,03 0, 1 7 0,77 4,41 
CBZ: Carbamazepine 
EPOXY: 10,11-epoxy-carbamazepine 
DI-OH: 10,11-dihydro-10,11-dihydroxy-carbamazepine 
TABLE 14: MEA...."I\J CONCENTRATIONS ( J.lg/ml) OF CARBAMAZEPINE 
AND METABOLITES IN EPILEPTIC RESPONDERS. 
INITIALS CBZ EPOXY DI-OH PB* PHT* 
AvA 7,58 1,04 2,74 
VP 4,84 0,56 2,13 
RI 8,58 2,39 3,43 
KS 5,87 1,11 3,34 10 
JA 4,16 0,57 1,81 10 
JT 7,91 1,15 2,91 
RT 6,47 0,98 2,37 
DN 6,29 0,91 1,94 
DH 4,04 0,51 1,60 
ss 4,05 0,56 1,17 
BR 5,98 o,4o 1,95 
MA 4,41 0,87 1,84 
CBZ: Carbamazepine 
EPOXY: 10,11-epoxy-carbamazepine 
DI-OH: 10,ll-dihydro-10,11-dihydroxy-carbamazepine 
PH: Phenobarbitone 
PHT: Phenytoin 
* These drugs were assayed by the service laboratory of 
the Pharmacology Department, University of Cape Town, 
using the EmitR method for antiepileptic drugs. Values 
are mean concentrations (µg/ml). 
84 
* 
TABLE 15: MEAN CONCENTRATIONS (µg/ml) OF 
CARBAMAZEPINE AND METABOLITES IN EPILEPTIC NON-
RESPONDERS. 
INITIALS CBZ EPOXY DI-OH PB* PHT 
MF 4,94 0,89 4,59 
BG 8,07 1,38 4,69 
GP 7,77 1,98 6,28 20 
RA 5,74 1,20 3,93 
MC 9,49 2,10 5,59 
QJ 7,99 1,97 7,28 20 12 
MB 7,35 1,66 4,30 10 
JN 11,59 3,45 7,66 10 
cc 4,07 0,78 3,20 15 
RC 3,68 1,27 2,82 15 
SH 7,67 1,37 6,00 
CBZ: Carbamazepine 
EPOXY: 10,11-epoxy-carbamazepine 
DI-OH: 10,ll-dihydro-10,11-dihydroxy-carbamazepine 
PB: Phenobarbitone 
PHT: Phenytoin 
These drugs were assayed by the service laboratory of 
* 
the Pharmacology Department, University of Cape Town, 
using the EmitR method for anti-epileptic drugs. Values 
are mean concentrations (µg/ml). 
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CHAPTER FOUR 
DISCUSSION AND CONCLUSIONS 
• 
CHAPTER FOUR 
4.1. Discussion 
4.1.1. Side-effects 
Carbamazepine has been reported to cause a wide variety 
of side-effects such as drowsiness, ataxia, nausea and 
vomiting, skin rashes, depression and confusion, and various 
haematological abnormalities (review by Gayford and Redpath 
19 6 9) • 
However, it must be stressed that these side-effects 
are often manifested at the start of therapy and usually dis-
appear on continuation of the treatment. 
Hoppener et al (1980) monitored carbamazepine serum 
levels between 8 a.m. and 6 p.m. in 43 epileptic patients. 
A threshold level of 8 µg/ml was reported above which inter-
mittent side-effects - diplopia, drowsiness and headaches -
were likely to occur. This study confirmed earlier reports 
by Parsonage (1972), Meinardi (1972) and Schneider (1975) who 
suggested that the clinician could prevent serious side-
effects by ensuring that the carbamazepine serum level 
is below 8 to 9 µg/ml. 
It is unfortunate, however, that the main metabolites 
of carbamazepine, viz. 10,11-epoxy-carbamazepine and 10,11-
dihydro-10,ll-dihydroxy-carbamazepine were not monitored in 
these studies. Both metabolites are only approximately 50% 
bound to plasma proteins (based on simultaneous cerebrospinal 
fluid/plasma level measurements, Schneider and Berenguer 1975) 
therefore quite a large fraction of these metabolites can 
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enter the central nervous system and they may in fact play 
a role in the manifestations of side-effects. 
In this study 6 out of the 23 patients complained of side-
effects; nausea and headaches were the most frequently 
mentioned complaint (Table 11). In the 6 patients, side-
effects occurred with a peak in the serum level of carbamaze-
pine (figs. 14 to 17). 
In the responder group, the mean peak serum level of 
carbamazepine in the patients with side-effects was 8,18 µg/ml 
compared with 6,11 µg/ml in the patients without side-effects. 
In the non-responder group, the mean peak serum level of 
carbamazepine in the patients with side-effects was 8,99 µg/ml 
compared with 8, 41 p.g/ml in the patients without side-effects. 
The point must be made here that patients in the non-responder 
group were apparently too concerned with the uncontrolled 
nature of their seizures to complain about side-effects. 
The randomization test for two independent samples showed, 
however, that there was no significant difference between 
the mean peak levels of carbamazepine in patients, both with 
or without side-effects, in either the responder or non-
responder groups. Therefore, a threshold level above which 
side-effects are likely to occur could not be defined. 
In the case of 10,11-epoxy-carbamazepine and 10,11-
dihydro-10,ll-dihydroxy-carbamazepine, again statistical 
analysis showed that there was no significant difference 
in the serum levels of these metabolites in patients, both 
with or without side-effects. Thus, no definite conclusion 
could be reached as to whether the metabolites play a role 
in the manifestation of side-effects. 
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For the three patients in the responder group, reduction 
in the morning dose of carbamazepine brought about a dis-
appearance of side-effects with still very good control of 
seizures. As regards the three patients in the non-responder 
group, the problem was more complex because a balance had to 
be struck between seizure control, such as it was, and the 
incidence of side-effects. Patients MF and JN had their 
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drug regimen changed, while for patient RA, the neurologist 
decided that the side-effects were not severe enough to warrant 
a reduction in dosage (see Appendix B, Case Studies, for more 
details.) 
It is interesting to note that these six patients who 
complained of side-effects had been taking carbamazepine for 
at least a year. The side-effects were not spontaneously 
mentioned and would have escaped notice if attention had not 
been focussed on them. The patients believed that drowsiness, 
nausea and headaches were connected with their epilepsy and 
they accepted it, more so because in the past very little 
attention had been paid to their complaints. The clinician 
must therefore focus his attention on possible side-effects 
occurring with a peak in the level of carbamazepine and make 
specific enquiries about these reactions and monitor serum 
levels at intervals during the day if there .is any doubt 
about toxicity. 
4.1.2. Role of the metabolites in the therapeutic efficacy 
of carbamazepine 
The chemical and physical properties of carbamazepine 
are such that it can be classified as a neutral, lipophilic 
compound (Faigle et al 1976). The lipid solubility is 
attributable to its tricyclic framework, and its neutral 
character can be ascribed to the fact that the nitrogen atoms 
in the azepine ring and carbamoyl side chain are part of a 
urea moiety (fig. 1). 
The body possesses no mechanism by which exogenous lipo-
philic substances, including especially those of neutral 
character, can be excreted in unchanged form (Weiner 1967). 
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In the case of carbamazepine, it has been found in man that 
only about 1% of the drug is excreted unchanged in the urine 
and 70% in the form of metabolites; the main one being 10,ll-
dihydro-10,11-dihydroxy carbamazepine (Faigle and Feldman 1975). 
As a result of this rather extensive metabolism, 
attention was focussed on the possibility that 10,11-epoxy-
carbamazepine and 10,ll-dihydro-10,11-dihydroxy-carbamazepine 
could perhaps play a role in the overall anticonvulsant 
activity of carbamazepine in man. 
Carbamazepine and metabolites were therefore administered 
as single oral doses to mice and rats and tested for anti-
convulsant activity (Frigerio and Morselli 1975; Schmutz et 
al (1979). From the ED-50, the dose required to protect 50% 
of the animals against convulsions induced by electric shock 
or cardiazol, it was found that only 10,11-epoxy-carbamazepine 
could significantly add to the anti-epileptic effect of 
carbamazepine in patients. 
In the literature, only one report is to be found in 
which the correlation between seizure frequency and plasma 
metabolite concentrations has been investigated. Dam et al 
(1977) studied 132 epileptic patients who had been treated 
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for 1 to 8 years with carbamazepine either alone or in com-
bination with other anticonvulsants. Apart from carbamazepine, 
only 10,11-epoxy-carbamazepine was monitored. The authors 
anticipated that if 10,11-epoxy-carbamazepine had an anti-
epileptic effect of its own in man, then patients with high 
plasma level of this metabolite would have better seizure 
control. However, it was found that patients who had relatively 
higher levels of 10,11-epoxy-carbamazepine did not in fact 
have better seizure control. 
In agreement with the above study, I found that patients 
in the non-responder group had higher serum levels of 10,11-
epoxy-carbamazepine relative to those patients in the 
responder group (P <0,02). The higher epoxy metabolite levels, 
in the non-responders, were associated with a higher relative 
serum level of 10,ll-dihydro-10,11-dihydroxy-carbamazepine in 
these patients (P <0,002). 
This suggests, therefore, that the metabolites of 
carbamazepine are inactive in man, or that 10,11-epoxy-
carbamazepine is active (as in rats; Frigerio and Morselli 
1975) but that any likely therapeutic effect is counteracted 
by the relatively large concentration of 10,11-dihydro-10,ll-
dihydroxy-carbamazepine which has been shown to be inactive 
(Schmutz et al 1979). 
4.1.3. Why no response to carbamazepine? 
In the management of epilepsy, it is now accepted that 
patients must have an optimal level of anticonvulsant drug 
in their plasma in order to achieve control of seizures. 
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This optimu.~ concentration can be defined as that concentration 
of drug which brings about maximal control of seizures with 
the minimum of side-effects. 
For a drug like carbamazepine, it is better to speak of 
optimal levels because there is some difference of opinion 
about the therapeutic range (as is commonly the case when 
the range is based on data from several small trials, not 
always properly controlled analytically and statistically). 
A reasonable guess is that the optimal level can be as low as 
2 µg/ml to as high as 12 µg/ml (refer Chapter One, 1.3.4). 
In the various clinical trials reported in the 
literature, it has often been pointed out that it is not 
understood why certain patients with optimal levels of 
carbamazepine in plasma fail to respond to therapy. For 
example, Eichelbaum et al (1976) reported that in 13 patients 
suffering from partial complex seizures, carbamazepine levels 
of 5 µg/ml did not produce any improvement in the frequency 
of partial or generalised seizures. Increasing the dose in 
5 of those patients produced plasma concentrations of 7 to 8 
µg/ml; there was no improvement in seizure frequency and 
side-effects were seen. More recently, Strandjord and 
Johannessen (1980) reported that out of 62 patients taking 
part in a study to evaluate the efficacy of carbamazepine, 
as sole drug in the treatment of simple and complex partial 
seizures, 20% failed to respond to therapy even with optimal 
levels of carbarnazepine (5 to 8 µg/ml) and 10,11-epoxy-
carbarnazepine (0,4 to 1,2 µg/ml) in plasma. 
In agreement with these studies, I found that there was 
no statistically significant difference in the area under the 
plasma concentration/time curve (AUC) for carbarnazepine, 
between responders and non-responders. The AUC gives the 
overall concentration of carbarnazepine in the plasma of the 
individual patients of the two groups. Moreover, the mean 
concentration of carbarnazepine in the responder group ranged 
from 4,82 to 6,86 µg/ml (Table 17) and in the non-responder 
group the range of mean carbarnazepine concentrations was 
5,71 to 8,78 µg/ml (Table 18). 
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It is a well-known clinical impression that partial 
complex s.eizures are more resistant to anti-epileptic treatment 
than generalised (tonic-clonic) seizures. In this study, the 
patient population in the responder group consisted of six 
patients suffering from partial complex seizures and six 
patients with generalised (tonic-clonic) seizures. In the 
non-responder group, five patients had partial complex seizures 
and six patients suffered from generalised (tonic-clonic) 
seizures. Therefore, it can be seen that there was no bias, 
in the type of epilepsy, of the patient population of the two 
groups. 
The medication charts of the two patient groups are quite 
different (Tables 3 and 4). Six patients in the responder 
group were taking phenothiazines (chlorpromazine, fluphena-
zine, and clozapine). However, these drugs do not 
possess anticonvulsive properties and in fact it has been 
shown that grand mal or focal seizures may occur on pheno-
thiazines, especially in patients with a history of convulsive 
disorder (Simpson and Cooper 1978). 
Moreover, patients in the non-responder group did not 
differ markedly from the responders with respect to the cause 
of epilepsy (see Appendices A and B). The mean duration of 
epilepsy in the responders and non-responders was 12,3 years. 
The question, therefore, is how do we explain non-
response to carbamazepine in the presence of optimal levels 
of the drug in plasma? 
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Statistical analysis of available data reveals that the 
only difference between the patients in the responder and non-
responder groups, is the fact that the non-responding patients, 
although they have optimal levels of carbamazepine in plasma, 
also have in addition a higher concentration of 10,11-epoxy-
carbamazepine (P <0,02) and 10,11-dihydro-10,ll-dihydroxy-
carbama.zepine (P <O ,002). 
Cerebrospinal fluid (CSF) w~~ obtained from seven patients 
of the non-responder group. On ethical grounds, it was not 
possible to obtain CSF from responders, so a statistical 
comparison between the two groups could not be made. However, 
the mean (±SD) ratio of 10,11-epoxy-carbamazepine to carbamaze-
pine in the non-responders was 0,55±0,14 while the mean (±SD) 
ratio of 10,ll-6ihydro-10,ll-dihydroxy-carbamazepine to 
carbamazepine was as high as 1, 17± 0, 36 ( Table 16) . 
From the fact that the non-responding patients had a 
much higher concentration of 10,ll-dihydro-10,11-dihydroxy-
carbamazepine in plasma and CSF, it appears that this 
metabolite is as inactive in man as in animals (Schmutz et al 
1979) • 
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This has led me to put forward the hypothesis that certain 
patients fail to respond to carbamazepine, even with optimal 
levels of the drug in plasma, due to competition at the 
carbamazepine "receptor" sites in the brain by 10,ll-dihydro-
10,11-dihydroxy-carbamazepine. 
It must be pointed out that no actual receptor has been 
isolated for carbamazepine. The term "receptor" is being used 
to describe any system in the brain, with which carbamazepine 
is interacting, in order to produce its characteristic 
pharmacological effect, that is, preventing the spread of 
an epileptic discharge. 
It has been shown that carbamazepine may exert its 
therapeutic effect by blocking the accumulation of cyclic 
3',5'-adenosine monophosphate (cAMP). Cyclic AMP may play a 
vital role in epileptogenesis (Lewin and Bleck 1977). Koella 
et al (1976) showed that carbamazepine can block hippocampal 
after-discharge, thus explaining the possible benefit of the 
drug in temporal lobe seizures. The nucleus ventralis anterior 
of the thalamus has been implicated in the generation and 
spread of a seizure discharge. Carbamazepine has been shown 
to have a specific inhibitory action on the transmission of 
impulses at this particular site in the brain (Julien & Hollister 1975) 
Carbamazepine has also the ability to depress the excitability 
of membranes, thus raising the threshold for an epileptic 
discharge (Schauf et al 1974). 
At all these possible sites of action of carbamazepine, 
competition by the inactive 10,ll-dihydro-10,11-dihydroxy-
carbamazepine will result in a reduced therapeutic effect 
of the drug. 
Patients in the responder group had very good control 
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of their seizures (see Appendix A) with low levels of 10,11-
dihydro-10,ll-dihydroxy-carbamazepine in their plasma. There-
fore, it may be postulated that the binding of this metabolite, 
at the possible sites of action of carbamazepine, occurs on a 
competitive basis and that patients not responding to therapy, 
with high plasma metabolite levels, may have the frequency 
of their seizures improved by blocking the production of 10,ll-
dihydro-10,11-dihydroxy-carbamazepine. 
4.1.4. Why high metabolite concentrations in non-responders? 
No statistical difference could be demonstrated between 
the concentration of carbamazepine in the responder and non-
responder groups. Yet the non-responders had a higher 
concentration of the metabolites present in their plasma. 
The daily oral intake of carbamazepine (mg/day) was found to 
be statistically higher for patients in the non-responder 
group compared with patients in the responder group (P <0,05). 
Therefore it is not unlikely that the patients in the non-
responder group were metabolising carbamazepine faster than 
the patients in the responder group, thus obtaining similar 
carbamazepine levels in plasma but higher levels of 10,11-
epoxy-carbamazepine and 10,ll-dihydro-10,11-dihydroxy-
carbamazepine. 
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Six patients in the non-responder group were taking pheno-
barbitone and/or phenytoin as concurrent medication with 
carbamazepine. It could therefore be argued that the high 
metabolite concentrations in the non-responders could have 
been due to enzyme induction by these drugs, An interaction 
demonstrated by Christianssen and Dam (1973) and confirmed by 
Johannessen and Strandjord (1975) and Schneider (1975). 
However, no significant difference in absolute concentration 
of the metabolite was found in patients on polypharmacy and 
patients that were on carbamazepine monotherapy in that group. 
This suggests that these patients were already in an auto-
induced state and their metabolism was not influenced by either 
phenobarbitone or phenytoin. 
The phenothiazines are hydroxylated by the cytochrome P-450 
system of the liver, which activates molecular oxygen for the 
oxidation of these lipid soluble substances. Drugs that are 
metabolised by the same oxidizing system of cytochrome P-450 
will compete with each other for metabolism. For example, 
thioridazine has been shown to block the metabolism of 
phenytoin (Vincent 1980). 
The formation of 10,11-epoxy-carbamazepine and 10,ll-
dihydro-10,11-dihydroxy-carbamazepine is catalysed by the 
enzymes mono-oxygenase and epoxide hydrase, respectively. 
These enzymes form an intricate part of the cytochrome P-450 
oxidizing system of the liver. It is possible, therefore, 
that concurrent administration of phenothiazines could well 
have an inhibitory effect on the metabolism of carbamazepine. 
However, in this study, differences in serum concentration of 
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10,11-epoxy-carbamazepine and 10,ll-dihydro-10,11-dihydroxy-
carbamazepine between the 7 patients on phenothiazines and 
the 5 on carbamazepine monotherapy, could not be demonstrated 
statistically. 
10,ll-dihydro-10,11-dihydroxy-carbamazepine is the main 
metabolite isolated from urine (approximately 35% of the dose), 
one-third of which is in the form of a glucuronide conjugate 
(Richter et al 1978). The high concentration of this 
metabolite present in the non-responders could therefore 
have been partly due to a clearance problem in these 
individuals. 
In the elimination of a metabolite from the body, there 
are two processes involved: (a) the rate of formation, and 
(b) the rate of elimination of the metabolite. The general 
assumption is that the rate of elimination is always greater 
than the rate of formation since metabolites are considered 
to be polar compounds and hence readily eliminated from the 
body. This assumption may be true when polar conjugates such 
as glucuronides, sulphates and glycine conjugates are the major 
metabolites formed. However, the assumption need not be true 
when biotransformation results in acetylation or oxidation 
(Gibaldi and Perrier 1975). 
Since the serum urea and creatinine were within normal 
limits in both responders and non-responders (see Appendix C) 
it may be assumed that the rate of elimination of 10,ll-dihydro-
10,11-dihydroxy-carbamazepine was the same in both groups of 
patients. The high levels of the dihydroxy metabolite in 
the non-responders could therefore perhaps be explained by 
a greater rate of formation. 
There was a greater diurnal fluctuation (mean±SD) in 
the serum level of carbamazepine in the non-responders 
(45±13%) than in responders (36±20%). This suggests a shorter 
half-life of the drug in the non-responders as a result of a 
greater rate of metabolism. However, the time to reach peak 
concentrations and the peak levels attained showed wide inter-
individual variations in both responders and non-responders 
and these factors may also have contributed to the diurnal 
fluctuations in serum levels. 
The mixed function oxidases (cytochrome P-450), which 
includes the enzymes mono-oxygenase and epoxide hydrase, are 
subject to nutritional and genetic control, so the amounts 
of epoxides and diols produced will vary from individual to 
individual (Garner 1976). Moreover, it has been suggested 
on the basis of results obtained from controlled studies in 
twins, that genetic factors are more important than 
environmental factors in determining the rates of drug 
metabolism in man (Vesell 1972). Identical twins, even when 
living in different environments, still metabolise drugs at 
114 
the same rate, demonstrating genetic control of drug metaboli.sm. 
Isoniazid,which is used in the chemotherapy of tuberculosis, 
is a classic drug whose metabolism has been shown to be under 
genetic control (La Du 1972). Many other examples exist 
in the literature. 
It is conceivable therefore that a sub-population of 
patients exists that are fast metabolisers of carbamazepine, 
and these are the patients that fail to respond to carbamazepine 
even with therapeutic levels of the drug in plasma. 
Cigarette smoke contains the polycyclic hydrocarbon, 
benzo(a)pyrene, and this compound has been shown to have the 
ability to induce liver enzymes (Nebert et al 1974). 
For example, peak plasma levels of phenacetin at two hours 
were significantly lower in average smokers than in non-
smokers after a 900 mg dose. Ratio of plasma metabolites 
as total N-acetyl-p-aminophenol (paracetamol) and phenacetin 
were higher in smokers than in non-smokers 
Although the effect of smoking is apparently a selective 
process, at present it is not possible to predict which drugs 
will be affected. Nevertheless, it is now thought that the 
smoking habit should be considered as one of the primary 
sources of drug interactions in man (Park and Breckenridge 
1981). 
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In this study there were no unusually heavy smoking 
habits in patients of the non-responder group compared with 
patients in the responder group and therefore it is unlikely 
that cigarette smoking could be the reason for high metabolite 
levels in non-responders. 
If the ratio of 10,ll-dihydro-10,11-dihydroxy-carbamaze-
pine to carbamazepine is measured at 6 hours after a dose, 
and the data analysed using the Student's t distribution, 
it is found that there is a 9S% ~hance that a 
patient with a ratio of greater than 0,55 will be a non-
responder. 
4.1.5. Clinical implications 
Clinicians with a good understanding of clinical 
pharmacology tend to adjust the dose of a drug to the needs 
of the individual patient. Fast metabolisers of the drug 
will have their dose increased in order to achieve better 
seizure control, whereas slow metabolisers will have their 
dose reduced in order to avoid toxic effects. 
In the case of carbarnazepine, this study presents results 
which suggest that increasing the dose in fast metabolisers 
116 
of the drug, may have virtually no beneficial therapeutic 
effect. Like most drugs, carbarnazepine is metabolised by a 
first order process (Perucca et al 1980). The metabolism of 
carbarnazepine is peculiar, however, in that the two metabolites 
considered are lipophilic and not readily excreted so that 
they may persist in the blood and presumably also in the fatty 
tissues of the central nervous system. Therefore increasing 
the dose in a fast metaboliser may produce greater concen-
trations of metabolites in the body. If 10,ll-dihydro-10,11-
dihydroxy-carbarnazepine does indeed interfere at the sites of 
action of carbarnazepine in the brain, then no improvement in 
seizure control will be expected. 
All patients on carbarnazepine should therefore have both 
10,11-epoxy-carbarnazepine and 10,ll-dihydro-10,11-dihydroxy-
carbarnazepine levels monitored. Patients who are found to 
have high levels of metabolites and are also non-responders 
should either have the drug withdrawn or in some way have 
the metabolism blocked by administration of an oxidative 
enzyme inhibitor. 
4.2. Conclusions 
(1) The investigational design used in this study has shown 
that 10,11-epoxy-carbamazepine and 10,ll-dihydro-10,11-
dihydroxy-carbamazepine do not play any apparent role in the 
overall therapeutic efficacy of carbamazepine nor in the 
manifestation of side-effects. 
(2) Non-response to carbamazepine, despite optimal levels 
of the drug in plasma, is most probably due to competition 
by 10,ll-dihydro-10,11-dihydroxy-carbamazepine at the sites 
of action of the drug in the brain. 
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4. 3. Suggestions for further work 
This study has shown that there is a possibility that 
the metabolite 10,ll-dihydro-10,11-dihydroxy-carbamazepine 
competitively inhibits the sites of action of carbamazepine 
in the brain. In order to prove or disprove this hypothesis, 
further investigations must be carried out. 
(1) Animal studies 
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Seizures to be induced in rats or mice by means of an 
alternating current (50-100 volts, 50 c.p.s., for 0,63 seconds, 
applied through corneal electrodes). Carbamazepine then to be 
injected intrathecally, one hour prior to the electric shock, 
in increasing doses and the ED50 value to be estimated, i.e. 
the dose required to protect 50% of the animals against tonic 
extension seizures of the hind limbs. (Intrathecal injection 
is necessary in order to avoid metabolism.) 
Two hours after the injection of the ED 50 dose of 
carbamazepine, increasing doses of the metabolite 10,11-
dihydro-10,ll-dihydroxy-carbamazepine to be injected. If 
the incidence of tonic convulsions of the hind limbs increases, 
the metabolite might indeed be competing with the action of 
the parent substance in the brain. 
(2) In vitro studies 
From its structure it appears that carbamazepine may 
have a certain degree of affinity for the dopamine or 5-
hydroxy-trytamine (5-HT) receptor. 
A radiotracer assay, using a radio-labelled form of a 
compound known to bind to either the dopamine or 5-HT receptor 
with high affinity, should therefore be set up. 
The nonradioactive form of carbamazepine then to be 
added in increasing concentrations and the percentage binding 
of radio-labelled compound against concentration of 
carbamazepine plotted. This gives the relative affinity of 
the drug for the receptor. The same procedure then to be 
repeated with the nonradioactive form of the metabolite, 
10,ll-dihydro-10,11-dihydroxy-carbamazepine. If similar 
curves are obtained, then the possibility exists that the 
metabolite competes with the drug at that particular receptor 
site. However, a negative result will not mean that in vivo 
competition by the metabolite at the sites of action of the 
drug does not take place. 
(3) Clinical studies 
Drugs like cimetidine and propoxyphene have been shown 
to have the ability to inhibit the metabolism of carbamazepine 
(Dam and Christiansen 1977 1 . Telerman-Toppet et al 1981). 
An experimental study could be set up to investigate 
whether inhibition of metabolism by the above drugs, in a 
non-responder, results in an improvement in seizure control. 
(4) Carbamazepine polymorphism 
The possibility exists that the metabolism of carbamaze-
pine is under genetic control. In order to examine this, 
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blood concentrations of carbamazepine and the dihydroxy 
metabolite should be measured at 6 hours after a standard 
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dose in a large number of subjects. If a bimodal distribution 
is then found, slow and fast metabolisers of the drug probably 
exist. However, since carbamazepine induces its own metabolism, 
subjects should be in steady state conditions before blood 
sampling. 
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APPENDIX A 
CASE STUDIES OF PATIENTS IN THE RESPONDER GROUP: 
1. Patient: AvA 
Sex: Female 
Age: 20 
Race: White 
Folder no.: 22001327 
History: 
Onset of epilepsy: This patient has been suffering from 
idiopathic epilepsy for the past nine years. 
Seizure pattern: Grand mal attacks with a photosensitive 
component. 
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Drug therapy: She was started on phenytoin which made her 
hirsute; phenobarbitone made her aggressive; clonazepam gave 
her rhisus sardonicus; sodium valproate gave her a persistent 
vaginal discharge. Her seizures were poorly controlled on 
these drugs. 
In 1978, carbamazepine 200 mg three times a day was 
started which was gradually increased to 1 000 mg per day; 
this resulted in relatively good control. However, she has 
been complaining of headaches and nausea. On reducing the 
morning dose from 400 mg to 200 mg, these side-effects have 
disappeared with still very good control of her seizures. 
Investigations: 
EEG: Abnormal (mild) 
Mild generalised irregular theta on alpha background. 
Tfiis patient is a non-smoker. 
2. Patient: VP 
Sex: Female 
Age: 35 
Race: Coloured 
Folder no.: 635084 
History: 
Onset of epilepsy: This patient has been suffering from 
idiopathic epilepsy for the past ten years. 
Seizure pattern: Grand mal seizures. 
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Drug therapy: She was started on phenobarbi tone. (30 mg three times 
a day) and phenytoin (100 mg twice a day). Her seizures were 
never fully controlled on this drug regimen, and in 1975 
carbamazepine 200 mg twice a day was introduced. There was 
a marked reduction in her seizure frequency and she was there-
fore gradually weaned off phenobarb and phenytoin, and her 
carbamazepine dose increased to 400 mg twice a day. 
She has had no further seizures since she has been on 
carbamazepine monotherapy (three years). However, she 
suffered from frontal headaches and nausea usually 
around lunchtime; this corresponded to a peak in the blood 
level of the drug. On reduction of the morning dose from 
400 mg to JOO mg her headaches have decreased in frequency 
and intensity. She still has good control of her seizures. 
Investigations: 
EEG: Normal 
Alpha rhythm 
Ihis patient is a non-smoker. 
J. Patient: RI 
Sex: Female 
Age: 19 
Race: Coloured 
Folder no.: 72212662 
History: 
Onset of epilepsy: This patient has been suffering from 
idiopathic epilepsy for the past six years. 
Seizure pattern: Grand mal seizures. 
Drug therapy: She was started on a drug regimen consisting of 
phenobarbitoneandphenytoin. Her seizures were never fully 
controlled by these drugs, and therefore in 1978 sodium 
valproate 200 mg three times a day was introduced after 
discontinuing phenobarbitone. However, there was almost no 
improvement in her seizure frequency. It was decided, there-
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fore, to phase out phenytoin and sodium valproate and introduce 
carbamazepine at 100 mg twice a day, building it up to 200 mg 
twice a day. On this regimen, she has had relatively good 
control of her seizures. However, she has suffered from 
severe headaches and drowsiness after taking the morning 
dose. This corresponded to a peak in the blood level of 
the drug. On reducing the morning dose from 200 mg to 100 mg 
the headaches have reduced in intensity with still good 
control of seizures. 
Investigations: 
EEG: • Abnormal 
Irregular generalised theta 
No focar area of discharge 
This patient is a non-smoker. 
4. Patient: KS 
Sex: Male 
Age: 27 
Race: Coloured 
Folder no.: MCO 10789 
History: 
Onset of epilepsy: This patient sustained a head injury at 
the age of 12 years and developed seizures at the age of 16 
years. 
Seizure pattern: Grand mal seizures with focal onset. 
Drug therapy: He was started on phenytoin at 100 mg three 
times a day. This was found to have very little effect in 
controlling his seizures. The regimen was therefore 
supplemented by carbamazepine 200 mg mane and 400 mg nocte. 
On this regimen he has had good control for the last five 
years. 
He also has episodes of overt aggressive behaviour 
which are controlled on clozapine 200 mg nocte. 
Investigations: 
EEG: Abnormal 
Right temporal focus consistent with temporal lobe 
epilepsy 
N.B.: This patient is under institutionalized care. 
This patient smokes 10 to 20 cigarettes per day. 
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s. Patient: JA 
Sex: Male 
Age: 38 
Race: Coloured 
Folder no.: MC 10146 
History: 
Onset of epilepsy: This patient developed idiopathic 
epilepsy at the age of 24 years. 
Seizure pattern: This is characterised by a loss of 
consciousness which is preceded by gustatory and auditory 
auras. Post-ictally there is a marked confusional state. 
Drug therapy: He was started on phenytoin 200 mg twice a 
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day but this was found to have very little effect in controlling 
the seizures. Primidone was added but there was no improvement 
.After discontinuing primidone, carbamazepine 200 mg twice a 
day was introduced. There was a marked reduction in seizure 
frequency and phenytoin was reduced to 100 mg twice a day. 
No seizures have been recorded for the past three years on 
this drug regimen. 
The patient also has an underlying behavioural problem 
which is controlled on clozapine 200 mg nocte. 
Investigations: 
EEG: Normal 
Alpha rhythm 
N.B.: This patient is under institutionalized care. 
This patient smokes 10 to 20 cigarettes per day. 
6. Patient: JT 
Sex: Male 
Age: 21 
Race: Coloured 
Folder no.: MCO 1857 
History: 
Onset of epilepsy: This patient sustained a head injury 
at the age of 11 years and developed seizures at the age of 
16 years. 
Seizure pattern: This is characterised by episodic 
psychotic behaviour and depressed level of consciousness. 
Drug therapy: The patient was admitted in December 1980 at 
Valkenberg Mental Hospital and he was diagnosed to be 
suffering from temporal lobe epilepsy. There was no history 
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of previous treatment. He was therefore placed on carbamazepine 
200 mg three times a day and no seizures were observed over 
the six months' hospital stay. 
Investigations: 
EEG: Abnormal 
Interictal pattern with strong support for left 
temporal lobe focus 
This patient smokes 10 to 20 cigarettes per day. 
7. Patient: RT 
Sex: Male 
Age: 33 
Race: White 
Folder no.: MWC 2185 
History: 
Onset of epilepsy: This patient fell out of a tree onto 
his head at the age of st years and subsequently developed 
seizures. 
Seizure pattern: Grand mal seizures. 
Drug therapy: He was on a drug regimen consisting of pheno-
barbitone JO mg three times a day, phenytoin 100 mg three 
times a day, and carbamazepine 200 mg three times a day for 
a number of years. Polypharmacy did very little to control 
his seizures. He was gradually weaned off phenobarbitone and 
phenytoin and since he has been on carbamazepine monotherapy 
no seizures have been recorded (five years). He also has 
psychotic episodes which are controlled on chlorpromazine 
100 mg twice a day. 
Investigations: 
EEG: 
CT-Scan: 
Abnormal 
Generalised irregularity 
Cortical atrophy 
This patient smokes 10 to 20 cigarettes per day. 
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8. Patient: DN 
Sex: Male 
Age: 27 
Race: White 
Folder no.: MW 8416 
History: 
Onset of epilepsy: This patient was involved in a motor 
vehicle accident at the age of 5 years and sustained a 
fracture of the occiput, and fractures of the legs. He 
was unconscious for approximately 6 months. He underwent 
neurosurgery at the age of 13 years and subsequently 
developed seizures. 
Seizure pattern: Grand mal seizures. 
Drug therapy: He was started on phenobarbitone and phenytoin 
which did little to control his seizures. In 1975, 
carbamazepine 200 mg twice a day was introduced and he was 
gradually weaned off phenobarbitone and phenytoin. 
regimen he has had no attacks (three years). 
On this 
He also has episodes of overt aggressive behaviour 
which are controlled on fluphenazine 25 mg. 
Investigations: 
EEG: Abnormal 
Generalised irregularity 
No focal onset 
N.B.: This patient is under institutionalized care. 
This patient 1s a non-smoker. 
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9. Patient: DH 
Sex: Male 
Age: 42 
Race: White 
Folder no.: MW 8415 
History: 
Onset of epilepsy: This patient has been having seizures 
for the past eleven years. He is also mentally retarded. 
Seizure pattern: Grand mal seizures. 
Drug therapy: In 1978, he was started on carbamazepine 
200 mg twice a day and this was found to control his 
seizures effectively. There is no previous history of drug 
treatment. 
He also has psychotic episodes which are controlled 
on fluphenazine 25 mg. 
Investigations: 
EEG: Abnormal (mild) 
Mild non-specific irregularity 
N.B.: This patient is under institutionalized care. 
This patient is a non-smoker. 
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10. Patient: ss 
Sex: Male 
Age: 34 
Race: White 
Folder no.: MW 8875 
History: 
Onset of epilepsy: This patient was involved in a motor 
vehicle accident at the age of 20 years and developed 
seizures at the age of 24 years. 
Seizure pattern: This is characterised by auditory and 
visual auras followed by loss of consciousness, and a post-
ictal confusional state. 
Drug therapy: In 1980 he was started on carbamazepine 
200 mg twice a day, which resulted in good control. There 
is no previous history of drug treatment. 
He also has episodes of psychotic behaviour which 
are controlled on clozapine 100 mg twice a day and 
chlorpromazine 100 mg nocte. 
Investigations: 
EEG: Normal 
Alpha rhythm 
This patient smokes 10 to 20 cigarettes per day. 
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11. Patient: BR 
Sex: Female 
Age: 32 
Race: European 
Folder no.: 53730552 
History: 
Onset of epilepsy: This patient has been suffering from 
idiopathic epilepsy since the age of 2 years. 
Seizure pattern: This is characterised by nausea 
and vomiting which may sometimes proceed to a tonic-clonic 
phase. 
Drug therapy: Phenobarbitone and phenytoin had very little 
effect in controlling her seizures. In 1972 carbamazepine 
in a dose of 200 mg three times a day was introduced and 
gradually increased to 1 200 mg daily while the other 
anticonvulsants were gradually discontinued. On this 
regimen she has had good control. 
Investigations: 
EEG: Abnormal 
Left temporal lobe abnormality, greater anteriorly. 
This patient is a non-smoker. 
• 
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12. Patient: 
Sex: 
Age: 
Race: 
Folder no.: 
History: 
Onset of epilepsy: 
20 years. 
MA 
Male 
23 
White 
MW 7003 
Seizure episodes started in 1978 at 
Seizure pattern: This is characterised by auditory and 
visual auras, followed by loss of consciousness. 
Drug therapy: He was started on carbamazepine at a dose 
of 100 mg twice a day which was then increased to 200 mg 
twice a day. On this regimen he has had good control 
( one year). 
He also has underlying schizophrenic behaviour and 
he is taking chlorpromazine 700 mg daily and orphenadrine 
200 mg daily. 
Investigations: 
EEG: Abnormal 
Right temporal focus 
This patient smokes 10 to 20 cigarettes per day. 
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APPENDIX B 
CASE STUDIES OF PATIENTS IN THE NON-RESPONDER GROUP: 
1. Patient: 
Sex: 
Age: 
Race: 
Folder no.: 
History: 
MF 
Female 
32 
White 
50077494 
Onset of epilepsy: This patient was involved in a motor 
vehicle accident at the age of 17 years and subsequently 
developed seizures. 
Seizure pattern: This is characterised by loss of concen-
tration, nausea, biliousness (no vomiting) and abdominal 
distension. It may then proceed to a tonic-clonic phase 
and loss of consciousness. 
Drug therapy: She was tried on a variety of anticonvulsants 
including phenobarbitone, phenytoin, sodium valproate and 
clonazepam with poor control. 
In 1979 she was admitted for control of her seizures 
and started on carbamazepine 800 mg daily. On this drug 
regimen her attacks varied in frequency from 2 to 4 a month 
to several months without an attack. By the end of 1980 
her attacks increased in frequency to as many as 4 in a week. 
Carbamazepine was increased to 1 000 mg daily but there was 
no improvement in seizure frequency. On this dose she 
suffered side-effects such as drowsiness, nausea and head-
aches. Early this year her dose was decreased to 800 mg 
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daily although the side-effects decreased slightly in 
intensity they were still present. She was admitted in 
March this year for control of her seizures. On admission, 
blood carbamazepine levels were 6,J µg/ml. 
Apart from her anticonvulsant drugs, the patient has 
also been taking domperidone (JO mg daily) and magnesium 
trisilicate (1 000 mg daily) for gastric complaints. 
Investigations: 
VDRL: 
CSF: 
Negative 
Clear colourless fluid. Protein O,l g/1, 
sugar J,2 mmol/1. No cells. 
CT scan: Normal 
EEG: Abnormal 
Bitemporal abnormality, greater on right. 
In keeping with inter-ictal record. 
Course and Management: 
Initially the patient was getting one attack per day 
at around 11 a.m. Eventually she was controlled on sodium 
valproate 400 mg three times a day orally and carbamazepine 
200 mg three times a day orally. She was discharged on the 
above medication as well as sucralfate 2 tabs. twice a day 
orally and sennasides J nocte. 
This patient smokes 20 cigarettes per day. 
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2. Patient: BG 
Sex: Female 
Age: JJ 
Race: White 
Folder no.: 195328 
History: 
Onset of epilepsy: This patient has been having seizures 
since the age of 9 years. 
Seizure pattern: This is characterised by an 'acidic taste' 
which precedes a disturbance of consciousness and amnesia 
for a few minutes. No clonic episodes are associated with 
these seizures. 
Drug therapy: She was started on carbamazepine which was 
only partly effective in controlling the seizures. CT scan 
showed the presence of an epidermoid extending into the 
temporal horn of the lateral ventricle. In December 1977 
the cyst was successfully removed surgically. She was started 
on phenytoin 100 mg three times a day which was then increased 
to 400 mg/day. Improvement in seizure frequency occurred for 
a while. However, in January 1980, carbamazepine was reintro-
duced (200 mg twice a day) after an increase in frequency 
of attacks. No improvement occurred. Phenytoin was with-
drawn and carbamazepine increased to 800 mg daily. 
adequate control was achieved. 
Investigations: 
EEG: Abnormal. 
Still no 
Left temporal lobe abnormality greater anteriorly 
on alpha background. 
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Course and Management: 
The patient was not admitted but carbamazepine was 
reduced to 200 mg three times a day and sodium valproate 
200 mg three times a day was introduced. On this regimen 
seizure frequency decreased from 8 per week to 4 per week. 
fhis patient is a non-smoker 
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3. Patient: GP 
Sex: Female 
Age: 24 
Race: Coloured 
Folder no.: 9.2188294 
History: 
Onset of epilepsy: This 24 year old woman has been an 
epileptic for the past 11 years. She attributes the beginning 
of her problem to her being hit by her father. 
Seizure pattern: Grand mal attacks with a photosensitive 
element. 
Drug therapy: She was started on phenytoin and phenobarbitone 
which did little to control her seizures. Phenytoin was 
phased out and carbamazepine 400 mg twice a day was introduced 
in 1978. Since she has been on this drug regimen, her 
seizures improved but in the month prior to entry in the 
study, as many as 10 attacks were recorded. On admission, 
carbamazepine levels were 8,8 µg/ml and phenobarb 20 µg/ml. 
Investigations: 
VDRL: 
CSF: 
Negative 
Clear colourless fluid, no increase in globulin, 
protein 0,1 g/1. No cells. Sugar J,l mmol/1. 
CT scan: Normal 
EEG: Abnormal 
Inter-ictal, greater left, would query fronto-
. 
temporal focus and photosensitivity. 
Course and Management: 
Whilst in the ward, the patient was gradually weaned 
off phenobarb. Sodium valproate 200 mg three times a day 
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was introduced and carbamazepine was reduced to 200 mg 
three times a day. The patient was found to be well 
controlled on this drug regimen and she was discharged. 
This patient is a non-smoker. 
4. Patient: 
Sex: 
Age: 
Race: 
Folder no.: 
History: 
RA 
Male 
17 
White 
82332230 
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Onset of epilepsy: This patient has a background of epilepsy 
since the age of 12 years. 
Seizure pattern: This was initially generalised, with 
tonic-clonic convulsions and loss of consciousness, but 
towards the end of 1977 he began to see coloured dots moving 
up and down and obscuring his vision, followed by intense 
sleepiness and severe frontal throbbing headaches. 
Drug therapy: The frequency of these episodes and the 
grand-mal seizures were reasonably well controlled by 
phenytoin 100 mg twice a day and carbamazepine 400 mg twice 
a day. After a period of time it was decided to gradually 
phase out phenytoin and leave the patient on carbamazepine 
monotherapy. The patient's seizures were still reasonably 
well controlled for almost a year when he had a sudden 
increase in his partial seizures. Increase in the dose of 
carbamazepine to 1 200 mg per day had no beneficial effect 
and he was admitted in August 1979, after a recurrence of 
grand mal seizures. 
pine was 11,2 µg/ml. 
On admission, blood level of carbamaze-
The patient was discharged on carbamazepine 400 mg 
twice a day and ethosuximide 500 mg twice a day. Control of 
the attacks although not complete appeared adequate. However, 
since the beginning of this year, the partial complex seizures 
have increased in frequency and in the month prior to 
entry into the study, up to seven attacks were recorded. 
Investigations: 
EEG: 
CT-scan: 
Abnormal 
Inter-ictal with right-sided focus 
Possible temporal lobe artefact 
Course and Management: 
The patient complained of drowsiness, especially in 
the afternoon. This corresponded to a drug level of 7,1 µg/ 
ml. However, the symptom was not severe and the neurologist 
thought it best to continue the same regimen for a further 
period. 
This patient is a non-smoker. 
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5, Patient: MC 
Sex: Male 
Age: 45 
Race: White 
Folder no.: 57497653 
History: 
Onset of epilepsy: This 45 year old man has had epilepsy for 
the last 20 years. There is no history of head trauma. 
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Seizure pattern: This is characterised by an aura for 15 
seconds, feeling cold and a premonition, thenthe seizure itself 
is an intense burning in the head, with very vivid distorted 
thoughts. The patient becomes detached and unaware of his 
surroundings. His pupils dilate, his eyes stare, he feels 
very weak. Seizures last about two minutes. 
Drug therapy and progress: He was on phenobarbitone and 
phenytoin for 17 years which only controlled his generalised 
seizures. In May 1980 he was admitted because his partial 
complex seizures had become more frequent, as many as 12 attacks 
in a day. Angiography and CT-scanning showed the presence of 
a very large arterio-venous malformation in the right tempera-
parietal region. It was decided that the lesion was too large 
to offer a safe chance of successful removal. The patient was 
therefore started on carbamazepine 400 mg mane and 500 mg nocte. 
His seizures have been reasonably well controlled for the last 
nine months but recently as many as 10 to 15 attacks have been 
recorded in a month. 
Investigations: 
EEG: Abnormal (mild) 
Mild right-sided slow, greater anterior parasagittal. 
Course and Management: 
It was decided against admitting the patient and to 
continue the same drug regimen for a further period. 
This patient is a non-smoker. 
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6. Patient: Q.J 
Sex: Female 
Age: 17 
Race: Coloured 
Folder no.: 59091132 
History: 
Onset of epilepsy: This 17 year old girl has been an epileptic 
since the age of 4 years. 
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Seizure pattern: The fits apparently involve loss of conscious-
ness for approximately 5 minutes with a tonic phase although 
there is no biting of the tongue or any incontinence. Focal 
abnormal movements have also been noted involving twitching of 
the toes, ankles and l~ps with some lip smacking. 
Drug therapy: The patient had been medicated for years on pheno-
barbitone JO mg three times a day and phenytoin 100 mg three 
times a day. In August 1980, the frequency of seizures 
increased and carbamazepine 400 mg twice a day was added. No 
improvement in seizure frequency occurred and approximately 20 
fits per month have been recorded. 
Examina ti on: A well looking young girl with evidence of 
hirsutism and gum hypertrophy. There were no localising 
neurological signs. 
Investigations: 
VDRL: 
CSF: 
CT-scan: 
Negative 
Clear colourless fluid, no globulin. Protein 
0,1 g/1, one lymphocyte. CSF glucose normal. 
Posterior fossa cut rotated with unexplained 1,2mm 
shift of the midline towards the right side. 
Drug levels: On admission - phenobarb 27 µg/ml; phenytoin 
JO µg/ml; carbamazepine 9 µg/ml. 
EEG: Abnormal 
Multi-focal epileptic inter-ictal with? left 
temporal lobe focus 
Course and Management: 
The patient was admitted for investigation and control 
145 
of her epilepsy. It was decided to stop phenobarb and phenytoin 
and to continue on carbamazepine alone. No seizures were 
recorded whilst in the ward. After being discharged, seizures 
have still continued even with optimal levels of carbamazepine -
8,J µg/ml - in plasma. 
This patient is a non-smoker . 
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7. Patient: MB 
Sex: Male 
Age: 19 
Race: Coloured 
Folder no.: 54287974 
History: 
Onset of epilepsy: In 1977 this patient was involved in a 
motor vehicle accident. On admission to hospital he underwent 
elevation of a depressed skull fracture and was unconscious 
for a number of days. He was incontinent of urine for quite 
a while after the injury and was unable to walk. He has had 
very poor vision in the left eye and seizures since the accident. 
Seizure pattern: Grand mal seizures. 
Drug therapy: The patient was discharged from hospital on 
phenytoin (JOO mg daily) and phenobarbitone (90 mg daily). 
However, his seizures remained uncontrolled. After changing 
his drug regimen to phenytoin 200 mg twice a day and carbamaze-
pine 200 mg twice a day, his seizure frequency improved for a 
while. 
In January this year there was an increase in the grand 
mal attacks; carbamazepine was increased to 800 mg daily but 
no improvement in seizure frequency occurred. On the day of 
admission for investigation of his seizures, the patient had 
four attacks. Blood level of carbamazepine was 5 µ.g/ml and 
phenytoin 20 µg/ml. 
Investigations: 
EEG: Abnormal 
Right hemisphere slowing, greater temporally 
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VDRL: Negative 
CSF: Clear colourless fluid. Protein 0,1 g/1, sugar J,2 
rnmol/1. No cells. 
Course and Management: 
Carbamazepine was increased to JOO mg three times a day 
and phenytoin was gradually discontinued. Whilst in the ward, 
no seizures were recorded (ten days). On being discharged 
from hospital, seizures still occurred even with blood levels 
of carbamazepine in the upper limit of the therapeutic range 
(8,2 µg/ml). 
This patient smokes 10 to 20 cigarettes per day. 
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8. Patient: JN 
Sex: Female 
Age: 20 
Race: White 
Folder no.: 56613847 
History: 
Onset of epilepsy: This patient has been an epileptic since 
early childhood. 
Seizure pattern: Grand mal seizures. 
Drug therapy: Until recently her seizures have been fairly well 
controlled by phenobarbitone 90 mg daily and carbamazepine 
l 000 mg daily. However, a month or so before entry into the 
study, as many as lO to 15 seizures were recorded. Blood 
levels on admission were: 
phenobarbitone 20 µg/ml. 
Investigations: 
VDRL: Negative 
EEG: Abnormal 
carbamazepine 9 µg/ml and 
General spiking activity occurring intermittently 
and unassociated with symptoms 
Course and Management: 
The patient complained of nausea and headaches after 
the morning dose of carbamazepine. This was found to correlate 
with a blood level of 14,76 µg/ml. The morning dose was there-
fore reduced from 400 mg to 200 mg. Intravenous clonazepam 
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was found to produce a distinct improvement in her EEG. The pheno-
barbitone was therefore withdrawn and clonazepam introduced. 
The patient was discharged on carbamazepine 800 mg daily and 
clonazepam 1mg daily. 
9, Patient: cc 
Sex: Female 
Age: 16 
Race: Coloured 
Folder no.: 59427088 
History: 
Onset of epilepsy: This 16 year old girl has been an epileptic 
since the age of 7 years. There is no history of birth trauma 
or accidents, nor is there a family history of epilepsy. 
Seizure pattern: Her attacks are characterised by falling to 
the ground after turning slowly to her right. Her upper limbs 
go into spasmodic fusion, as do the digits. Her lower limbs 
are in full extension. Her eyes turn towards the right. She 
then lapses into unconsciousness. 
Drug therapy: She was initially treated with phenobarbitone 
and phenytoin; however, she developed gum hypertrophy and 
therefore phenytoin was phased out and carbamazepine 200 mg 
three times a day was introduced. Since she has been on this 
drug regimen, she has had a minimum of one seizure a week and 
was admitted for control of her epilepsy. On admission, the 
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blood levels of carbamazepine and phenobarbitone were 7 µ g/ml and 
15 µg/ml, respectively. 
Investigations: 
VDRL: Negative 
CSF: 
EEG: 
Clear colourless fluid. No increase in globulin. 
Sugar J,2 mmol/1. 
Abnormal 
Protein 0,2 g/1. 
Interictal with right hemispheral focus, greater 
frontally. 
Course and Management: 
Sodium valproate 200 mg three times a day was introduced 
and phenobarbitone and carbamazepine gradually phased out. 
No fits were recorded whilst the patient was on sodium 
valproate monotherapy. Patient was discharged on sodium 
valproate 800 mg per day. 
This patient is a non-smoker. 
150 
10. Patient: RC 
Sex: Male 
Age: 44 
Race: Coloured 
Folder no.: 55656854 
History: 
Onset of epilepsy: This patient was well witil 1978 when he 
started having seizures. There is no history of head trauma 
and no family history of epilepsy. 
Seizure pattern: Grand mal seizures. 
Drug therapy: Phenobarbitone and phenytoin were prescribed 
but did not control his seizures. In 1979 phenobarbitone was 
withdrawn and carbamazepine 200 mg three times a day intro-
duced. Seizures still persisted and phenytoin was increased 
to 500 mg daily. 
In July 1980 he was admitted via the Casualty Department 
in status epilepticus. Blood levels of carbamazepine and 
phenytoin were in the therapeutic range. The patient was 
treated along the routine lines for status epilepticus with 
intravenous diazepam and phenytoin. No cause for the 
deterioration in seizure control could be fowid and the 
patient was discharged on phenytoin 100 mg mane, 200 mg nocte 
and carbamazepine 400 mg twice a day. 
The patient has been complaining of increased fits 
recently, despite taking his medication. In Jwie this year 
he was re-admitted in status epilepticus. Blood levels of 
carbamazepine and phenytoin were again in the therapeutic 
range. 
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Investigations: 
VDRL: 
CT-scan: 
Negative 
Normal 
X-ray of skull: Normal 
EEG: Abnormal 
Bilateral generalised slow wave activity 
Course and Management: 
The patient responded to intravenous diazepam. The 
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same dosage of his oral medication (i.e. 800 mg daily carbamaze-
pine and JOO mg daily phenytoin) was continued whilst in the 
ward. No fits were recorded (five days) and he was discharged 
on the same drug regimen. 
This patient smokes 20 cigarettes per day. 
11. Patient: 
Sex: 
Age: 
Race: 
Folder no.: 
History: 
SH 
Female 
10 
White 
59744623 
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Onset of epilepsy: This patient has been having seizures 
for the past J to 4 years. 
Seizure pattern: These are characterised by a 'frightening 
feeling' after which she vomits. Occasionally she also 
experiences a sense of disorientation with respect to time, 
place and person, with no associated clonic component. 
Drug therapy: She was placed on carbamazepine therapy 200 mg 
three times a day with initial good effect but the attacks 
have occurred more frequently since December 1980. She was 
admitted in June this year for investigation and control of 
her seizures. 
Investigations: 
CT scan: Normal 
X-ray skull: Normal 
VDRL: Negative 
EEG: Abnormal 
General slow sharp waves. Greater bilaterally, 
posteriorly and greater on the right. Inter-ictal 
pattern with strong support for right temporal focus. 
Course and Management: 
Patient was changed to carbamazepine 100 mg three times 
a day and sodium valproate 200 mg three times a day orally. No 
seizures were recorded whilst in the ward and she was discharged 
on this drug regimen. 
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APPENDIX C (contd.) 
TEST 
SODIUM (Na+) 
POTASSIUM (K+) 
UREA 
CREATININE 
TOTAL PROTEIN 
ALBUMIN 
ALKALINE PHOSPHATASE (ALK. PHOS.) 
GAMMA-GLUTAMYL TRANSFERASE (GGT) 
ASPARTATE TRANSAMINASE (AST) 
ALANINE TRANSAMINASE (ALT) 
WHITE CELL COUNT (wee) 
RED CELL COUNT (Rec) 
HAEMOGLOBIN (Hb) 
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ADULT NORMAL RANGE* 
. -1 135-140 mmol 9., 
3,5-5 mmol 9., -1 
1,7-6,7 mmol Q,-1 
75-115 µmol 9.,-1 
60-80 -1 g Q, 
35-50 g 9.,-1 
30-85 UNITS 
0-50 UNITS ci 
0-40 UNITS Q,-1 
0-53 UNITS 9.,-l 
4-11 X 109 9,-l 
m: 4,5-5,9 x 1012 z-l 
f: J,7-5,3 X 1012 cl 
g d n-1 m: 13,3-17,J ;,,, 
6 6 n-1 f: 11, -15, g d;,,, 
* As quoted by the Chemical Pathology and Haematology 
Laboratories of Groote Schuur Hospital, Cape Town. 
APPENDIX D 
Statistical Methods 
(1) Correlation coefficient 
The correlation coefficient (r) was calculated from 
the formula: 
r = 
E (x - i) (y - y) 
/E(x - i)2 E(y - y) 2 
where x: is the independent variable 
and y: the dependent variable. 
(The relationship of yon x can be represented by a 
simple equation called the regression equation, i.e.: 
y =a+ bx where a= y intercept and b = slope.) 
-x: the mean of x observations 
y: the mean of y observations. 
In order to test whether the correlation coefficient 
was significant, the t value was calculated from the 
formula: 
t = ~n - 2) 
I (1 - r 2 ) 
The significance of the observed value of the 
correlation coefficient was then determined from the t 
distribution table* for - 2 degrees of freedom. 
* From Siegel, S. (1956): Non-parametric statistics for 
the behavioral sciences. 
McGraw Hill, Kogak:usha Ltd. 
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(2) Mann-Whitney U test 
The U statistic was calculated from the formula: 
= 
or equivalently 
where 
= 
= 
= 
= 
= 
the number of subjects in the smaller of the two 
independent groups 
the number of subjects in the larger group 
the sum of ranks assigned to the group whose sample 
size is n 1 
the sum of ranks assigned to the group whose 
sample size is n 2 
The smaller value of U was the one used to test the 
null hypothesis by use of the Mann-Whitney statistical 
tables.* 
* From Siegel, S. (1956): Non-parametric statistics for 
the behavioral sciences. McGraw-Hill, Kogakusha Ltd. 
(J) The Randomization Test for two independent samples. 
This test was used to determine whether there was a 
significant difference in the peak (or mean) levels of 
carbamazepine in patients both with or without side-effects. 
Let n 1 = number of patients with side-effects 
n 2 = number of patients without side-effects. 
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Under the null hypothesis, it was merely a matter of chance 
that certain levels of either drug or metabolites were 
labelled A and others were labelled B, where A and B were 
patients with and without side-effects, respectively. The 
assignment of the labels A and B to the levels of drug and 
metabolites in the particular way observed might be conceived 
as one of many equally likely accidents if the null hypothesis 
were true. 
The randomization test specifies a number of extreme 
possible outcomes which could occur with n1 + n 2 scores, 
and designates these as the region of rejection. When we 
have \nl :
1
n2l equally likely occurrences under the null 
hypothesis, for some of these the difference LA (the sum 
of group A's scores) and LB (the sum of group B's scores) 
will be extreme. The cases for which these differences 
were largest constituted the region of rejection. 
If was the significance level, then the number of 
possible outcomes that constituted the region of rejection 
was The particular outcomes chosen to 
constitute that number were those outcomes for which the 
difference between the mean of the A's and the mean of the 
B's was largest. These were the occurrences in which the 
difference between LA and LB was greatest. The null 
hypothesis would have been rejected at the significance 
level a, if the sample obtained was among those cases listed 
in the region of rejection. 
The exact probability (one-tailed) of the occurrence 
of the observed levels of drug or metabolites under the 
null hypothesis wasp= 0,95. 
Therefore the null hypothesis could not be rejected. 
(See Siegel, S. (1956): Non-parametric statistics 
for the behavioral sciences. McGraw-Hill, Kogakusha Ltd. 
Page 152.) 
(4) The Spearman Rank Correlation Test 
The Spearman rank correlation coefficient (rs) was 
calculated from the formula: 
r = 1 
s 
where: 
d 2 = the square of the difference between the ranks of 
the x and y variables 
n = the number of observations of either x or y. 
The significance of the Spearman rank correlation 
coefficient was determined by calculating the t value: 
t 
r ./ (n - 2) 
= s 
-------
./ (1 - r 2) 
s 
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(5) Student's t distribution 
This test was used to determine whether there was a 
significant difference between the mean ratio of the 
concentrations of 10,ll-dihydro-10,11-dihydroxy-carbamazepine 
to carbamazepine, at 6 hours after a dose, between responders 
and non-responders and to calculate the 95% confidence limits 
of the mean ratio above which we can expect a patient to be 
a non-responder. 
The t statistic was calculated from the formula: 
- -
t = X - y 
where: 
-X = mean ratio for patients in the non-responder group 
-y = mean ratio for patients in the responder group 
n = number of patients in the non-responder group 
m = number of patients in the responder group 
s 2 = combined variance. 
formula: 
It was calculated from the 
s 2 
X 
s 2 y 
The 
the 
2 
s = 
(n - 1) sx2 + (m - 1) 
n + m - 2 
= variance of X = [rx p: x}2 J/ n - 1 n 
= variance of y = [LY (L y}2 ]/ m - 1 n 
95% confidence limits above and below the mean for 
non-responders were calculated from the formula: 
161 
X + t ;-;;-S2X 
- 0,05 /s ... _ 
and similarly, the 95% confidence limit above and below 
the mean for the responders was calculated from the formula: 
y ± to,05 fa y 
The upper limit of the mean ratio for the responders and 
the lower limit of the mean ratio for the non-responders 
were averaged out. This gave the ratio of metabolite to 
drug above which a patient had a 95% chance of being a non-
responder. 
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APPENDIX E 
The Trapezoidal Rule 
This method involves the description of a given plasma 
concentration-time curve by a function that depicts the 
curve as a series of straight lines, thereby enabling the 
area under the curve to be divided into a number of 
trapezoids. The area of each trapezoid is easily calculated, 
and the sum of all areas of all trapezoids yields an estimate 
of the true area under the curve. 
n-1 
¢(t)dt = [ 
i-:::o 
2 
t. 
1 
n = number of trapezoids into which the plasma curve is 
divided. 
¢(t) = a function which describes a given plasma 
concentration-time curve but is linear between two 
plasma level-time points. 
t = time 
c = concentration 
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APPENDIX F 
EQUIPMENT AND MATERIALS USED, AND SUPPLIERS 
Carbamazepine 
10,11-epoxy-carbamazepine 
10,ll-dihydro-10,11-dihydroxy-
carbamazepine 
Benzene, ethyl acetate, 
methanol, concentrated hydro-
chloric and sulphuric acids 
(Analar, B.D.H. Chemicals, 
Poole, England) 
Silica gel 60 TLC 
Plates, dimensions 10 x 20 cm 
(Merck, Darmstadt) 
Universal UV lamp 
Type 29000 
(Camag, Muttenz, Switzerland) 
Sample applicator for thin-
layer chromatography (Eva 
Chrom, Switzerland) 
2 µl capillary (Minicaps, 
EM Hirschmann, Laborglas, 
West Germany) 
Sartorius electronic micro-
balance 
Zeiss KM3 chromatogram 
spectrophotometer 
) 
) 
) 
) 
~ 
) 
) 
) 
) 
) 
) 
) 
) 
) 
) 
Ciba-Geigy (Pty.) Ltd. 
7 2/7 4 Steel Road · 
Spartan 
Kempton Park 
Johannesburg 
R.S.A. 
Hickman and Kleber (Pty.) 
Ltd. 
P.O. Box 2953 
Cape Town 
8000 R. S .A. 
T & C Scientific Supplies 
(Pty.) Ltd. 
P.O. Box 2953 
Cape Town 
8000 R.S.A. 
Labotec Cape (Pty.) Ltd. 
P.O. Box 773 
Cape Town 
8000 R.S.A. 
Zeiss West Germany 
Optical Instruments (Pty.) Ltd. 
P.O. Box 4051 
Cape Town 
8000 R.S.A. 
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